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ABSTRACT
Prevalence of non-alcoholic fatty liver disease (NAFLD) and obesity both in
the young and adult population is increasing at an alarming rate globally.
Along with traditional risk factors, such as diet and sedentary life style,
exposure of environmental chemicals is suspected to be a risk factor for
metabolic disruption. Moreover, the ‘fetal basis of adult disease’ hypothesis
implicates that early life exposure to environmental chemicals is more
impactful in causing lipid homeostasis disturbances than exposure in maturity.
Nuclear factor E2 related factor 2 (Nrf2) is a cytoprotective transcription factor
known to combat oxidative stress. The contribution of Nrf2 to other cellular
functions, such as lipid homeostasis relevant to liver and adipose tissue is
relatively new emerging area. The work herein assessed the role of Nrf2 in
augmenting environmental chemical induced NAFLD and adipogenesis. CD-1
mice were exposed to bisphenol A (BPA) perinatally and peripubertally until
age of 5 week at 25 g/kg BW/day and effect of this exposure on hepatic lipid
disturbances was evaluated at pubertal (week 5) and adult age (week 39).
Developmental exposure of BPA increased hepatic lipid accumulation in both
young, as well as adult mice. BPA also increased Nrf2 expression in these
animals at both ages.

Nrf2 binding to predicted anti-oxidant response

elements on the Srebp-1c promoter, a master regulator of denovo lipogenesis,
elucidated a potential regulatory role of Nrf2 in lipogenesis. BPA exposure
also increased Nrf2 binding to this new putative ARE by about 2 fold.
Epigenetic reprogramming of chromatin upon developmental exposure of

environmental xenobiotics is a potential mechanism for increasing susceptibly
to diseases, such as like NALFD. BPA exposure from gestation day 8 through
purberty caused hypomethylation in select regions of promoters that encode
for proteins involved in lipogenesis (e.g. Srebp-1c), as well as the antioxidant
response (e.g. Nrf2). The work further depicts an undescribed role for Nrf2 in
the regulation of lipogenesis via regulation of Srebp-1c.
In connection to the findings above, as well as other findings in our laboratory
that pointed to Nrf2 having a role in promoting hepatic lipid accumulation, it
was decided to evaluate whether chemicals that induce lipid accumulation can
do so in association with Nrf2 activation.

Next, the role of Nrf2 in lipid

accumulation was further characterized using adipose tissue in presence of
perfluorooctane sulfonic acid (PFOS). In rodent and human preadipocytes,
PFOS exposure elevated adipogenic process by increasing expression of key
regulators of adipose differentiation.

PFOS-induced adipogenesis was

associated with increase in Nrf2 expression and its transcriptional activity.
In conclusion, the environmental contaminants, BPA and PFOS alter lipid
homeostasis in liver and adipose tissue respectively. Concurrent increase in
Nrf2 expression, and its transcription regulation on lipogenic mediators was
demonstrated.
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PREFACE
The following dissertation titled “Role of nuclear factor E2 related factor 2
(Nrf2) in environmental chemical induced hepatic steatosis and adipogenesis”
is presented in manuscript format.

There are three manuscripts in this

dissertation. First manuscript is a review, prepared for “Int J of Toxicology”,
and also serves as general background for manuscript two, three. Manuscript
two is formatted in “Hepatology” journal style, second manuscript is in
“Toxicology and Applied Pharmacology (TAAP)” style.

At the end of the

thesis, there are two ‘appendices’, which present data that has not been
included in any of the manuscripts, but was generated by student while
working towards PhD research.
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ENVIRONMENTAL ORIGIN OF METABOLIC DYSFUNCTION AND
DISTURBANCES OF LIPID HOMEOSTASIS
Prajakta C Shimpi, Angela Slitt

Biomedical and Pharmaceutical Sciences, University of Rhode Island,
Kingston RI, USA

______________________________________________________________
Manuscript prepared for submission to “Int J of toxicology”

1

1.1 ABSTRACT:
Prevalence of obesity and its associated metabolic disorders including nonalcoholic fatty liver disease (NAFLD), are rising at an alarming rate, and hence
need a careful search for all possible pathogenic factors contributing this
epidemic. Although imbalance of energy intake and energy expenditure is
considered most traditional risk factors for obesity and NAFLD, recently
“environmental obesogens” hypothesis is the gaining interest in research
community, which links exposure of environmental chemicals and obesity.
Terms like toxicants associated fatty liver diseases (TAFLD) are being
increasingly used. The current paper has reviewed some the most recent
findings of these obesogens and TAFLD contributing chemicals which are
studied in rodent, in-vitro model as well as human correlation studies.
Chemical exposures during vulnerable windows in development play a critical
role in etiology of diseases. This paper reviewed few developmental exposure
studies, which correlated positive correlation between concentration of
exposure of these xenobiotic and obesity phenotype both in human and rodent
model to understand fetal basis of adult diseases. However, most of studies
are only demonstrating link of environment and metabolic effect without
elucidating possible mechanism of pathogenesis. Further work is required to
better characterize the molecular targets responsible for environmental origin
of metabolic dysfunction and disturbances of lipid homeostasis.

2

1.2 Obesity. Globally the rising prevalence of obesity and its associated
diseases is major public health concern in adult, children as well as adolescent
population.

According to results from the 2011–2012 National Health and

Nutrition Examination Survey (NHANES), more than one-third (34.9%) of
adults were obese in United States (1). Childhood obesity prevalence is also
increasing at an alarming rate. It is estimated that 20.5% of adolescents (1219 years of age) and 17.7% children (6-11 years age) are obese (2). Obesity
is characterized by structural and functional changes to and distribution of
white adipose tissue (WAT) in body. Adipose tissue plays a prominent role of
balancing energy status of the body by storing excess of fat in form of
triglyceride. Initially, excess fat is stored in mature adipocyte, and because of
its plasticity it can expand by undergoing hypertrophy. Along with hypertrophy,
hyperplasia of adipocytes, which means increasing number of fat cells through
differentiation of stem cells to adipocyte lineage, can also contribute for
disturbances of normal lipogenic and lipolysis process of adipose tissue
(3). Apart from considering WAT as fuel storage depot, is also recognized as
an active endocrine organ because of secretion of hormones and cytokines
that play crucial role in maintaining of metabolic homeostasis like appetite,
inflammation and insulin sensitivity (4). Adipocyte biology is significant to
pathogenesis of obesity and hence maintenance of normal adipogenesis and
mature adipocyte is very significant.

Mature adipocytes form from its

precursor mesenchymal stem cells through adipogenesis process, which
involves very complex transcriptional cascade regulating programs. Multiple
transcription regulators, including CCAAT/ enhancer-binding proteins (Cebp ,
3

Cebp ), and peroxisome proliferator-activated receptor (Ppar- ), are involved
in inducing adipogenic programming (5).

1.3 Non-alcoholic Fatty Liver Disease (NAFLD). Obesity associated
disturbance of adipogenesis process has deleterious consequences on insulin
resistance, which can contribute to pathogenesis of metabolic syndrome
comprising type-2 diabetes, dyslipidemia, atherosclerosis, hypertension and
NAFLD. Prevalence of suspected NAFLD increased from 3.9% in 1988-1994
to 10.7% in 2007-2010. Globally, 10-39% and in United States 20% of
general adult population is suspected to have NAFLD (6). About 3-17% of
children in the United States are detected with fatty liver diseases. As
expected, nearly 75% adults and 38% children from overweight/ obese BMI
have NAFLD (7, 8). NAFLD is a broad spectrum liver disease ranging from
preliminary hepatic steatosis to more aggressive form of nonalcoholic
steatohepatitis (NASH), which in turn may lead to cirrhosis and hepatocellular
carcinoma (HCC). Although pathogenesis of NAFLD is not well understood,
globally accepted “two-hit hypothesis” explain the progression of disease.
“First hit” is associated accumulation of lipids, especially triglycerides, in the
hepatocytes

cytoplasm,

contributing

to

5%

or

more

of

the

liver

weight. Although steatosis is asymptomatic and reversible, this chronic fat
accumulation in liver triggers “second hit” covering various inflammatory
cytokines and oxidative stress. Steatotic liver is more susceptible for lowgrade inflammation and disease progression like steatohepatitis. Dyslipidemia
and lipid deposition in liver are not only involved in first hit of NAFLD. Non4

esterified free fatty acids not only contribute to the steatosis, but also in
hastening the progression to NASH, challenging two-hit hypothesis (9).
Recent research also points towards “multi-hit theory” as opposed to two hits
for pathogenesis of NAFLD- reviewed by (10). Considering the complexity of
steatogenesis, necroinflammation of the hepatocytes, oxidative stress and
fibrogenesis, multi-hit theory is being considered more thorough approach
towards pathogenesis of NAFLD.
Because of this increasing prevalence, numerous studies are focusing on
early diagnosis and treatment for NAFLD. There is no specific biochemical
marker or serological test for the diagnosis of NAFLD. Liver biopsy is the gold
standard for diagnosis and staging of NAFLD, particularly for the diagnosis of
NASH. Due to the invasive nature of liver biopsy and risk associated with
procedure, it cannot be extensively used for large-scale population. Different
imaging techniques like ultrasonography (US), computed tomography (CT),
magnetic resonance imaging and magnetic resonance spectroscopy have
been approved as noninvasive alternative methods to detect hepatic steatosis
(11, 12). Association of NAFLD with cardiovascular disease, type 2 diabetes,
cirrhosis, and hepatocellular carcinoma along with difficulty in diagnosis and
lack of exact therapeutic intervention for these conditions make NAFLD a
serious public health concern.
There are multiple sources that contribute to the hepatic fatty acid pool. 1)
Dietary TG that reach the liver as chylomicron particles from the intestine; 2)
Denovo synthesis in the liver under a transcriptionally regulated process; 3)
Fatty acid influx into the liver from lipolysis of adipose tissue in obese and
5

insulin-resistant state ; 4) diminished export of lipids from the liver in very-lowdensity lipoproteins; and 5) reduced oxidation of fatty acids. The accumulated
fatty acids are stored in liver in the form of TG, eventually contributing to
steatosis.
NAFLD pathogenesis may involve disturbances of proliferator-activated
receptor alpha (Ppar ) and/ or sterol regulatory element binding protein-1c
(Srebp-1c), transcription factors that control enzymes responsible for oxidation
and synthesis of fatty acids respectively. The regulation of lipid metabolism in
liver is usually integrated with adipose tissue. Both of these organs play a
very critical role in trafficking and handling of lipid based on energy status of
the body (13). Hepatic triglyceride (TG) can transport to adipose tissues in\
very low-density lipoprotein where TG can store. Under hormonal regulation,
fatty acids are released from adipose tissue and are transported to liver for
oxidation. The control of whole body lipid homeostasis is mainly depending on
efficient regulation of this cycle (14). Therefore, disturbances at one organ
lipid homeostasis can have an impact on the other organ. This is why NAFLD
prevalence is high in obese population, and it remains major cause of mortality
and morbidity in obese people.

1.4 Environmental chemicals and adipose tissue lipid alterations.
Imbalances of energy intake and energy expenditure either because of
sedentary lifestyle or some genetic predisposition are well-recognized risk
factors for obesity and NAFLD.

However, increases in rates of health

concerns like metabolic syndrome and co-ordinate increase in synthetic
6

chemical production, toxic burden in our air, food and water since last few of
decades, it seems prudent approach to study the effects of the environmental
chemicals that are found in the majority of people, in increasing obesity
epidemic. It has generated significant interest of studying “nontraditional” risk
factors (e.g., environmental chemicals, stress, micronutrients, gut microbiome)
to the etiology of these health conditions. Moreover, because of lipophilic
property of most environmental chemicals like endocrine disruptors (EDC),,
adipocytes are an obvious target organ for their biological effects (15). Many
bioactive EDCs predicted to bioaccumulate in lipid droplets of mature
adipocyte that can be released into the systemic circulation slowly, which may
results into chronic exposure of chemical (16).
Alterations in adipose tissue function can modulate EDC flux from this storage
depot, thereby influencing the function of other metabolic tissues. In 2006
Blumberg and Grun postulated “environmental obesogen hypothesis”
suggesting possible link between environmental contaminants and the
epidemic of metabolic disease (17). Different classes of chemicals have been
proposed as environmental obesogens. Some examples include endocrine
disturbing chemicals (DES: diethylstilbestrol, genestein, BPA: bisphenol A and
it’s derivatives), organotins (TBT: tributyltin, TPT: triphenyltin, and DBT:
dibutyltin), organophosphate pesticicdes (parathion, diazinon, chlorpyrifos),
phthalates

(MEHP:

mono-ethylhexyl

phthalate,

DEHP:

di-2-ethylhexyl

phthalate), polyfluoroalkyl chemicals (PFOA: perfluorooctanoic acid, PFNA:
perfluorononanoic acid, PFOS: perfluorooctane sulfonic acid, and PFHxS:
7

perfluorohexane sulfonic acid), polybrominated diphenyl ethers(PBDE),
persistent organic pollutant (non-dioxin PCBs, HCB: Hexachlorobenzene ,
DDE: dichlorodiphenyldichloroethylene).

Human get exposed to these

chemicals on routine basis either through occupational or non-occupational
means.

Food, water, air contamination is the most common route of

exposure. Some chemicals get into food by leaching out of products that food
and beverages are stored. A prime example is BPA, which is used in
polycarbonate reusable food and beverage storage containers and the resin
lining of cans, which can lead to substantial levels of human exposure. PFAs
are stain repellent, and also used in firefighting foams, whereas PBDEs are
primarily used in flame retardant applications for manufacturing household
rugs, carpets, non-stick utensils and so on (18-21). Although actual acute
exposure of chemicals may be at nanomolar or lower concentrations,
persistent exposure through these routes cannot be ignored.
In order to assess environmental xenobiotic induced obesogenic effects,
numerous in-vivo as well as in-vitro approaches have been employed. Many
population epidemiological studies have identified intriguing link between
environmental chemical levels in biological fluids and metabolic syndrome
parameters. Importantly, although these human correlation studies provide
valuable information in predicting the risk associated with xenobiotic exposure,
precise mechanisms for underlying effects remain largely unknown. Table 1
summarizes representative human correlation studies which associate serum,
urinary, or tissue specific levels of xenobiotic with obesity parameters including
8

BMI, waist circumference, body weight, plasma insulin, leptin levels, systemic
inflammation and so on (22-31). Majority of these data are gathered from
participants of the National Health and Nutrition Examination Surveys
(NHANES).
3T3L-1 murine preadipocyte, adipocyte or bone barrow derived mesenchymal
stem cells (hADSC, mADSC), are most commonly used in-vitro model for
studying effect environmental chemicals on adipogenesis. Through in-vitro
studies, these chemicals are tested for its potential effect on adipogenic
differentiation and increasing number of fat cells in body. Alteration of
frequency with which MSCs are induced into adipogenic lineage to form
preadipocyte and the rate of differentiation of preadipocytes to adipocyte upon
exposure of these chemicals have been considered as one the possible
mechanism for their obesogenic nature. Table 2 enlists in-vitro studies of
chemicals tested for their adipogenesis potential (32-41).
For specific chemical induced obesogenic effects, in-vivo studies are also
conducted. Food intake, energy expenditure by using metabolic cages, body
weight, visceral and subcutaneous adipose tissue weight are some of the end
point considered while designing these in-vivo experiments.

Considering

adipose tissue as an endocrine organ, serum leptin, adiponectin, cytokine
levels are also considered as markers of adipose tissue hypertrophy or
hyperplasia. Moreover, physiological consequences of the lipid accumulation
including insulin resistance, glucose tolerance, urinary glucose elimination,

9

serum insulin levels, blood glucose levels, and serum lipid levels are
measured as advanced markers of obesity.
1.5 Environmental chemicals and hepatic lipid alterations. Liver is the
primary line of defense against potentially harmful xenobiotic therefore that is
target organ, most commonly affected by environmental chemicals. Attributing
to the relevance of environmental contaminants in inducing NAFLD in recent
years, term toxicants associated fatty liver diseases (TAFLD) and it’s sever
form toxicants associated steatohepatitis (TASH) were coined (42).

As

reviewed by Kneeman some of the xenobiotics like amiodarone, methotrexate,
tamoxifen and corticosteroids are implicated as possible contributing factors to
cause NAFLD (43).

The effect of numerous environmental/ industrial

chemicals enlisted by The Toxicological Reference Database (ToxRefDB,
EPA) and Chemical Effects in Biological Systems (CEBS, National Toxicology
Program) were studied for liver effects. Hundreds of chemicals including toxic
heavy metals (lead, mercury, cadmium, chromium), industrial chemicals
include organoclorine pesticides DDT and dieldrin, perfluolochemicals,
brominated fire retardants, PCBs, polyaromatic hyrocarbons, polychlorinated
and polybrominated diaxins and furans, polychlorinated naphthalenes,
fungicides, insecticides, biphenyls/dioxins, TCDD have potential to modify fat
metabolism in liver, and hence elevating the susceptibility to NAFLD (44, 45).
Although lots of chemicals have been suspected for their ability to induce fatty
liver independently of obesity, very few have been examined in-vivo. Table 5

10

enlists chemicals which have been tested in in-vitro as well as in-vivo, and
human correlation studies for their NAFLD inducing abilities.
As mentioned earlier, diagnosis of NAFLD is difficult and non-invasive
methods are not as reliable as biopsy, prevalence of NAFLD may be higher
than anticipated. As listed in table 5, environmental chemicals contribute to the
epidemic of the NAFLD, and unless disease progresses to advanced stages,
diagnosis is difficult, this points towards importance of the mechanistic
investigation of these environmental chemical induced effects. Few markers
used in in-vivo studies for NAFLD include hepatic and serum TG, free fatty
acid levels and oil red o staining of the frozen liver sections. Environmental
NAFLD warrants detailed mechanism based, and biomarker research in order
to better predict the prevalence in the population.
1.6

Mechanisms

of

the

environmental

chemical

induced

lipid

disturbances. Molecular mechanisms of these environmental exposure
induced dyslipidemia are largely unknown. Some of these chemicals are
structural ligands of lipogenic transcription factors whereas some other
chemicals like EDC interact of with hormone receptors and they mimic
endogenous hormones and thus disturb the programming of endocrine
signaling pathways and thus adipose tissue biology (46).

TBT is a Ppar-γ

ligand and thus stimulate adipogenesis. Because of having long carbon chain
in their structure, PFAs mimic fatty acid structures and bind to Ppar-α (47).
Phenylsulfamide and fungicide tolylfluanid mimic the action of endogenous
glucocorticoids and function as a glucocorticoids agonist and augment
11

adipogenesis in 3T3-L1 preadipocytes (48).
Owing to the rising prevalence of the childhood obesity and NAFLD, nutrition
and exposure to environmental chemicals during critical early life development
are newly emerging etiological factors of metabolic syndrome (49).

From

biomonitoring studies, several environmental chemicals that can cause obesity
in offspring because of gestational exposure were found in humans (49, 50).
Increasing evidences are being generated from animal studies of in-utero
exposure to relevant exposure levels of xenobiotics contributing to increase in
parameters of obesity/ NAFLD (summarized in tables 3, 4 and 5) (45, 51-68).
From the mechanistic point of view, it is likely that gene-environment
interactions and epigenetic modification of gene functions by alteration of DNA
methylation, histone acetylation, and chromatin remodeling that results in
genetic reprogramming (69). These epigenetic alterations during a vulnerable
window of development usually result in non-reversible changes in tissue
structure and function. These changes make body sensitize or programmed
eventually lead to increases incidences of variety of diseases later in life. This
hypothesis also referred as “fetal basis of adult diseases” (69).
For obesogenic compounds, few recent investigations link early epigenetic
reprogramming of the adipogenic process to the incidence of obesity in adult
life (37, 70).

1.7 Conclusion: Rising prevalence of dyslipidemic disorders suggests
etiological factors beyond traditional lifestyle and genetic predisposition.
12

Obesity and NAFLD increase risk of cardiometabolic diseases, as evident from
overlapping population prevalence. Moreover treatment of NAFLD is also a
concern, as currently there are barely any therapies available in market
targeting specifically on NAFLD/ NASH in people. Ongoing pharmaceutical
research on these therapies is also constantly challenged by difficulty of
diagnosis and unreliable non-invasive tools (71).
Based on research from government agencies, and also academic findings,
few of the manufacturing chemicals have been banned for use in some
countries, however, majority of chemicals listed in this review remain in
industrial use.

Also, the replacement chemicals being investigated for

manufacturing use seem to have similar structural and chemical profiles,
indicating real possibility of these new chemicals also not being risk-free.
Another issue with few such environmental chemicals is their prolonged halflife in nature as well as inside the living system.

PFAs exemplify

bioaccumulating chemicals that are not degraded to inactive form for years in
the food chain (72). Overall, rising awareness about environmental chemical
exposure contribution to the epidemic of obesity/ NAFLD seems imperative.
More studies are necessary for thorough mechanistic investigation of these
environmental origins of the childhood and adulthood diseases, so that
preventive or therapeutic approaches can be guided.
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2.1 ABSTRACT
Bisphenol A (BPA) is chemical used in manufacturing of consumer products
containing polycarbonate and epoxy resins. In humans, urinary BPA levels
have been positively associated with general and abdominal obesity, with
increased adverse liver effects described in children. Rodent studies have
demonstrated increased hepatic lipid accumulation after developmental BPA
exposure.

Nuclear Factor E2-Related Factor 2 (Nrf2) has been recently

shown to be a possible contributor to hepatic lipid accumulation.

It was

hypothesized that epigenetic changes occur before BPA-induced steatosis,
possibility via induction of Nrf2 expression.

Pregnant CD-1 mice were

administered 25μg BPA/kg/day via osmotic pump, and then after weaning on
postnatal day 21, the resulting daughters were exposed to BPA via drinking
water until PND 35. Tissues were collected at postnatal day 32 (Week 5) and
39 weeks of age and mRNA and protein expression profiling was performed.
BPA increased hepatic lipid content along with increased pro-lipogenic
enzyme mRNA and protein expression and induction of Nrf2 protein
expression at week 39. Transcription factor binding was assayed in liver by
chromatin immunoprecipitation (ChIP) and result showed at week 5 and week
39 , BPA exposure increased Nrf2 binding to a putative ARE consensus
sequence in the Srebp-1c promoter. Known Nrf2 activators increased Srebp1c promoter reporter activity in HepG2 cells. Effect on gene specific and CpG
site

specific

DNA

methylation

modification

of

was

assesses

by

immunoprecipation and pyrosequencing respectively. Hypomethylation of the
Nrf2 and Srebp-1c promoters was observed in livers from offspring that were
28

developmentally exposed to BPA.

Overall, the work herein presents new

findings that developmental BPA exposure induces fat accumulation via
hypomethylation of key lipogenic genes and promotes Nrf2 binding to the
Srebp-1c promoter.
Keywords: BPA, NAFLD, Nrf2, methylation, Srebp-1c, epigenetic
Abbreviations: Acetyl CoA carboxylase, Acc; antioxidant response element,
ARE;

2-microglobulin,

B2M;

Bisphenol

A,

BPA;

chromatin

immunoprecipitation, ChIP; fatty acid synthase, Fas; gestational day, GD;
glycerol 3 phosphate acetyl transferase, Gpat; glutamate cysteine ligase, Gclc;
methylated DNA immunoprecipitation, MeDIP; nonalcoholic fatty liver disease,
NAFLD; Nuclear factor E2 related factor 2, Nrf2; oil red o, ORO; peroxisome
proliferated activated receptor, Ppar; phosphate buffered saline, PBS;
postnatal day, PND; perinatal peripubertal, PNPP; sterol regulatory element
binding protein 1c, Srebp-1c; tris-buffered saline, TBS
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2.2 INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) is a broad-spectrum liver disorder.
American Association for Liver Diseases guidelines define NAFLD as the
presence of hepatic steatosis with no evidence of hepatocellular injury in the
form of ballooning of the hepatocytes (1).

In past two decades, NAFLD

prevalence has risen in adults and children, with suspected NAFLD having
increased from 3.9% in 1988-1994 to 10.7% in 2007-2010 (2). In addition to
more accepted risk factors such as obesity, energy imbalance, and sedentary
lifestyle (3), drugs and chemicals of environmental exposure have also been
implicated in increasing predisposition to NAFLD.

Multiple classes of

chemicals of environmental exposure including pesticides, insecticides,
dioxins, and polychlorinated biphenyls (PCBs) are potential modifiers of fat
metabolism in liver, and are suspected to increase the risk for developing
NAFLD (4, 5).
Specifically, exposure to Bisphenol A (BPA), a plastics component used in
manufacturing of polycarbonate and epoxy resins containing plastic bottles,
food containers, metal cans, and thermal receipts has been recently
associated with NAFLD (6, 7).

BPA exposure is ubiquitous, and it was

detected in more than 90% of the urine samples from the US population (8).
BPA has also been detected in human breast milk, amniotic fluid and cord
blood samples, which demonstrates the potential for fetal and neonatal
exposure (9-11).

A positive correlation between urinary BPA levels and

obesity risk has been reported in adults and children, especially in adolescent
females (12).

Recently, increased markers for NAFLD were positively
30

associated with urine BPA levels in a small cohort of children (13). Therefore,
there is growing health concern for early-life BPA exposure that has not been
fully addressed (14). In rodents, perinatal BPA exposure increased hepatic
lipid content and lipogenic gene expression, along with imbalance in adipokine
levels and insulin signaling disturbances in female offspring during
adolescence and adulthood (15-17). The mechanisms by which BPA induces
fat accumulation are largely undescribed, but likely involve induction of
lipogenesis through both direct (6) and epigenetic mechanisms (18).
Epigenetic mechanisms, such as DNA methylation and histone modifications
contribute to NAFLD (19-21). DNA methylation patterns and lipogenic gene
expression has been correlated in liver biopsy tissues from NAFLD patients
(22). Induction of fatty liver via a high-fat, high-sucrose diet was associated
with hypomethylation at some CpG sites and increased transcripts for
lipogenic proteins, such as sterol regulatory element binding protein 1c
(Srebp-1c) and glycerol-3-phosphate dehydrogenase (Gpat) (23). Similarly,
hypomethylation at specific CpG sites of the Fatty acid synthase (Fas)
promoter was induced by short-term or long-term high fat diet feeding and
correlated with up-regulation of Fas expression (24, 25). The mechanism by
which induction of Srebp1-c in rodents with early-life exposure to BPA has not
been elucidated, and it is hypothesized that it could also occur through
promoter hypomethylation (7).
Nuclear factor E2 related factor 2 (Nrf2) functions primarily as an antioxidant
defense system of the cell.

Recently, Nrf2 has been linked to adipose
31

differentiation and lipid homeostasis- reviewed by (26). Our previous work
suggests positive regulation of Nrf2 on hepatic lipid accumulation. In leptindeficient ob/ob mice, constitutive activation of Nrf2, by means of Keap1
knockdown, enhanced hepatic steatosis (27). Also, hepatic lipid deposition
and glucose tolerance worsened in Keap1 knockdown mice subjected to longterm high fat diet challenge (28). In rodent preadipocyte experiments, Nrf2
transcriptionally regulated Ppar-γ and Cebp-β to enhance adipocyte
differentiation and consequently lipid synthesis (29, 30).
Here, we studied how early life exposure to BPA through perinatal and
peripubertal exposure exerts epigenetic modifications in mice, and whether the
modifications persist into adulthood. First, it was hypothesized that PNPP
BPA exposure induces hypomethylation of CpG sites in promoters of lipogenic
genes (e.g. Srebp-1c and Fas) early in development, which would persist into
adulthood. Second, it was also determined whether Nrf2 expression increases
with BPA exposure, and whether it can be correlated with promoter
methylation status. Overall, our findings herein confirmed that PNPP BPA
exposure increases the expression of lipogenic enzymes in conjunction with
hypomethylation at CpG sites in the promoter regions.

Moreover, we

described increased Nrf2 recruitment to the Srebp-1c promoter in livers of
BPA exposed mice.
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2.3 MATERIALS AND METHODS
2.3.1 Animals and dosing. CD-1 female mice (10-12 weeks of age) and
proven breeder male mice (Charles River Laboratories, Wilmington, MA) were
maintained in temperature- and light-controlled (14/10-hr light/dark cycle)
conditions at the at Tufts University Human Nutrition and Research Center
animal facility (approved by the Association for Assessment and Accreditation
of Laboratory Animal Care International). All experimental procedures were
approved by the Tufts University New England Medical Center Institutional
Animal Care and Use Committee.

Cages, water, and bedding all tested

negligible for estrogenicity. Water was supplied ad libitum from glass bottles.
Food (Teklad 2018; Harlan, Indianapolis, IN) was supplied ad libitum. The
estrogenicity of food lots used was measured and found to be negligible (<20
pmol estrogen equivalents per gram of feed). Mice were paired to mate and
breed. The day on which a vaginal plug was detected, considered gestational
day 1 (GD 1). On GD 8, dams were implanted subcutaneously with Alzet
osmotic pumps (model 1004; Alza Corp., Palo Alto, CA) following the
manufacturer recommendations. Pumps were designed to deliver vehicle
alone (50% DMSO in water) and BPA (25 µg/kg bw/day). Care was taken to
limit BPA contamination through housing or feeding.

These exposures to

dams were continued until weaning age of pups, which is postnatal day 21
(PND 21) and pups exposed to BPA through lactation. After weaning age,
exposure of BPA to pups continued through drinking water until PND 32 (week
5). Livers and serum were collected from female pups at week 5 and at week
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39 and stored at -80°C until analysis (n=10 or 5/ group for week 5 and week
39 respectively).
2.3.2 Triglyceride quantification. Total lipids were extracted from liver tissue
by method previously described (28).

Briefly, liver tissue (50mg) was

homogenized in 1 ml of phosphate buffer saline (PBS) and extracted with
chloroform-methanol mixture (2:1). Lipid extracts were vacuum-dried by using
a Speedvac (Thermo Scientific) at 45°C. The lipid residue was re-suspended
in 1% Triton X-100 in 100% ethanol. Triglyceride quantification was performed
using a commercially available kit from Pointe Scientific Inc. (Canton, MI).
2.3.3 Oil Red O staining. About 5 μM thick sections were cut from frozen
liver tissue using Vibratome UltraPro 5000 Cryostat (GMI, Ramsey, MN, USA).
After acclimating to room temperature, the sections were fixed with 10%
buffered formalin for 10 min and then stained with Oil red O (ORO) working
solution. ORO stock solution was 0.5% Oil Red O in isopropanol. A fresh
working solution was prepared by combining 3 parts of stock solution with 2
parts of deionized water.

Tissue sections were incubated in the working

solution for 15 min at room temperature, the ORO solution was removed, and
sections were quickly rinsed 2 times with fresh 60% isopropanol. Sections
were next counterstained with hematoxylin, washed to water, and mounted in
glycerin jelly.
2.3.4 RNA isolation and quantitative real time PCR. Total RNA was isolated
using TRIzol reagent (Invitrogen, CA) according to the manufacturer’s
instruction. RNA concentrations were determined by using spectrophotometer
(Nanodrop ND1000, ThermoFischer Scientific, Waltham, MA, USA). 2μg of
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RNA was converted to single stranded cDNA using a High-Capacity cDNA
Reverse Transcription Kit (Invitrogen, Grand Island, NY). Expression of genes
at mRNA level were measured with quantitative real-time PCR using LightCycler® 480 and SYBR Green (Roche Applied Science, Mannheim, Germany)
detection system.

Levels of β2-microglobulin (B2M) used as reference

housekeeping gene to normalize all data. Lipogenic target genes such as
sterol regulatory element binding protein 1c (Srebp-1c), proliferator-activated
receptor –gamma (Ppar–γ), acetyl CoA carboxylase-1 (Acc-1), fatty acid
synthase (Fas) and glycerol 3 phosphate acyltrasferase (Gpat) and stearoyl
CoA desaturase-1 (Scd) were analyzed for mRNA expression and primers for
all these genes are listed in Supplementary table S1.
2.3.5 Determination of relative protein expression by western blot. 50mg
of liver tissue was homogenized in 1ml of RIPA buffer using a Dounce
homogenizer. The lysate was centrifuged a 12,000 rpm for 15 min at 4°C and
the resulting supernatant was collected as a total protein extract. Nuclear
proteins were extracted from liver tissue using a NE-PER® kit (Thermo
Scientific, Rockford, IL) and according to manufacturer's protocol. The extract
was quantified for protein content by a DC Lowry assay (Bio-Rad, Hercules,
CA). 30 μg of protein/well was resolved by SDS-polyacrylamide gel
electrophoresis and then proteins were transferred on PVDF membrane
(Millipore Corporation, Billerica, MA) at 100 V for 45 min. Membranes were
blocked with 5% non-fat dry milk in tris-buffered saline with 0.1% tween-20
(TBS-T). The membranes were then incubated overnight with primary antibody
diluted in 2% milk in TBS-T. Following washing with TBS-T, the membranes
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were incubated with species-specific peroxidase-labeled secondary antibody
(1:5000) in TBS-T for 1 hour at room temperature. Next, membranes were
washed in TBS-T, incubated in ECL+ (GE Healthcare, Waukesha, WI, USA).
The resulting protein bands were visualized by autoradiography films, which
were quantified using Quantity One software (Biorad, Hercules, CA). Specific
information about the source, dilution, type, and molecular weight of primary
and secondary antibodies is detailed in Supplementary Table S2.
2.3.6 Chromatin Immunoprecipitation (ChIP) assay. Chip assays using liver
tissues were performed according to the Active Motif ChIP-IT express kit
protocol with modifications (Active Motif, Carlsbad, CA). Briefly, 100 mg of
liver tissue was homogenized with 4 ml of phosphate-buffered saline
containing protease inhibitor. Homogenate was cross-linked by adding 1%
formaldehyde for 10 min and crosslinking was stopped by 125 mM glycine
solution. After washing twice with ice-cold PBS containing protease inhibitor
followed by centrifugation, the pellet was suspended in SDS-lysis buffer for 40
min on ice.

Dounce homogenizer was used to release nuclei from cells.

Lysates were sonicated using a Branson Sonifier 250 (Branson Ultrasonics
Corporation, Danbury, CT) 3 times with 12 seconds per stroke and a 1 min
rest in between. Cell debris was removed by centrifugation for 10 min at
12,000 g at 4°C.

Shearing efficiency was optimized to obtain chromatin

fragments between 200-800 bp and determined by 2% agarose gel
electrophoresis. A portion of sheared chromatin was used to determine the
DNA concentration and equal amount of sheared chromatin (equivalent to 15
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µg of DNA) was incubated with ChIP validated rabbit anti-Nrf2 antibody (C-20,
sc-722x, Santa Cruz Biotechnologies, Dallas, TX) or anti-rabbit IgG antibody
(Cell Signaling, Danvers, MA) overnight at 4°C with rotation. A portion of
sheared chromatin was preserved as input (10 µl).

Antibody-chromatin

complex was recovered by adding pre-blocked Dynabeads Protein A (Life
Tech, Grand Island, NY). Using magnetic racks, beads were pelleted and
sequentially washed. Antibody and beads bound to chromatin were eluted by
adding reverse crosslinking buffer and elution buffer sequentially. DNA was
purified by adding proteinase K and via phenol: chloroform: isoamyl alcohol
extraction. DNA fragments were analyzed by end-point PCR or real time PCR
using different primers that cover putative antioxidant response element (ARE)
sequences on mouse Srebp-1c, Fas, and Acc promoters (Supplementary table
S3).

Promoter sequences were identified using UCSC genome browser.

Results are represented as agarose gel scans (end-point PCR) as well as fold
enrichment (qPCR).
2.3.7 Methylation analysis:
A. Methylated DNA immunoprecipitation (MeDIP):

MeDIP assays were

performed as described previously by (31). Briefly, 6μg of genomic DNA was
sheared by series of 3×20 pulses of sonication using Branson Sonifier 250 at
power level 2 on the machine. Sonication efficiency was checked by agarose
gel electrophoresis and fragment size of DNA was verified approximately 500
kb. 350 μl of TE buffer was added to sonicated DNA and denatured at 95°C
for 10 min and then immediately placed on ice for 5 min. Sonicated and
denatured DNA was diluted with 100 μl of 5X IP buffer (50 mM Na-phosphate
37

pH7, 700 mM NaCl, 0.25% Triton X-100) and incubated with 5μg of 5methylcytosine

monoclonal

antibody

(5-mc)

(Epigentek

Group

Inc,

Farmingdale, NY) and with anti-rabbit IgG antibody (Cell Signaling, location)
overnight at 4°C with rotation. Protein A/G beads were prewashed with 0.1%
PBS-BSA and resuspended in 40 μl of 1X IP buffer. Beads were added to
DNA-Antibody complex and incubate for 2 hrs at 4°C on rotating platform.
Beads-DNA- antibody complex were washed three times with 1X IP buffer and
after washing complex were re-suspended in 250 μl of digestion buffer (50 mM
Tris HCl pH 8, 10 mM EDTA, 0.5%SDS) containing 3.5 μl of proteinase-k
(Sigma Aldrich, St. Louis, MO, USA) and then incubated at 55°C on a rotating
platform.

DNA purification was performed by phenol: chloroform: isoamyl

alcohol extraction, and resuspended in 30 μl of TE buffer.

Methylated

enriched DNA was amplified by real time PCR by using different primers that
covers CpG sites of promoter of Srebp-1c, Fas, and Nrf2 (Supplementary
table S4). Methylation status of these promoters was plotted in the form of
fold enrichment.
B. Pyrosequencing: DNA methylation quantitation of CpG sites was
performed by Pyrosequencing technology using PyroMark MD (Qiagen, Santa
Clarita CA). Firstly, Pyrosequencing assays for interest region of Nrf2
promoter were designed with PyroMark Assay Design Software version 2.0.
DNeasy Blood & Tissue Kit (Qiagen, Santa Clarita CA, catalog number:
69504) was used to isolate total genomic from frozen liver tissues and DNA
concentrations were determined by using spectrophotometer (Nanodrop
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ND1000, ThermoFischer Scientific, Waltham, MA, USA). Genomic DNA was
bisulfide converted by using EZ DNA Methylation™ Kit (Zymo Research,
Irvine, CA, catalog number: D5001). Briefly, sodium bisulfite was added to
approximately 1 μg of genomic DNA, converting unmethylated cytosines to
uracil, which are replaced with thymine during PCR; methylated cytosines
remain unchanged.

After bisulfite conversion, amplification of Nrf2 gene

regions of interest was performed using PyroMark PCR Kit (Qiagen, Santa
Clarita CA), forward primer (50 pmol), and biotinylated reverse primer (50
pmol) in a 25 μl PCR reaction system. The PCR conditions, forward, reverse
and sequencing primers and biotin labeling for all assays are shown in table 2.
The PyroMark MD Pyrosequencer platform (Qiagen) was utilized according to
manufacturer suggested protocol to quantify DNA methylation at the selected
CpG sites (computed by Pyro Q-CpG Software). Percent DNA methylation
calculated by standard curve by quantifying methylation of commercially
available 0% and 100% methylated control DNA (80-8060M-PreMix Mouse
Methylation Controls- Premix Set, EpigenDx Inc, Hopkinton MA) on each 96well plate.
2.3.8 Cell culture and transient transfection reporter gene assay:
Human Srebp1c promoter of 1565 bp corresponding to the 5′ upstream region
cloned in pGL3-basic luciferase vector was graciously donated by Dr. Marta
Casado (Instituto de Biomedicina de Valencia, Valencia, Spain). Expression
plasmid p3XFLAG-myc-CMV-26 (EV26) was obtained from Sigma-Aldrich (St
Louis, MO). NRF2 ORF cloned into EV26 was graciously donated by Dr. Jose
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Manautou (University of Connecticut, Storrs, CT). HepG2 cells were cultured
in DMEM containing 25mM glucose, 10% fetal bovine serum, 1% penicillinstreptomycin (10,000 U/mL) and 1% non- essential amino acid (NEAA) under
the humidified atmosphere of 95% air to 5 %CO2 at 37°C. Co-transfections
(Srebp1c luciferase reporter constructs and transcription factor expression
plasmids) were performed using Lipofectamine 3000 (Life Technologies,
Tarrytown NY) according to the manufacturer’s manual. For all transfections,
plasmid DNA used per well were 75ng for Srebp promoter construct, 15ng of
Nrf2 expression plasmid and 10ng null renilla luciferase (pRL-CMV) as internal
control. After 24 hrs of transfection, cells were lysed by 1× passive lysis buffer
and preceded for luciferase activity. For Nrf2 activator treatment experiments,
after 24 hrs of Sreb1c luc promoter plasmid transfection, cell were treated with
oleanolic acid (50uM) and sulforaphane (10uM) in 0.05% DMSO 12hrs. After
treatment, cells were lysed with 1× passive lysis buffer and luciferase activity
was measured relative firefly/renilla luciferase Dual-Luciferase® Reporter
Assay System (Promega, Madison, CA) with GloMaxTM Luminometer
(Promega, Madison, CA) according to manufacturer’s protocol.
2.3.9 Statistical Analysis. Control and treated groups were analyzed by
Student’s t-test. Asterisk * indicates statistically significant difference between
the control and BPA treated group (p<0.05).
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2.4 RESULTS
2.4.1 Effects of perinatal peripubertal bisphenol A (PNPP BPA) exposure
on body weight, liver weight and hepatic lipid accumulation. Prior to
present study, pilot study on PNPP BPA exposure was performed in both male
and female offspring. Initial data obtained from male mice did not indicate any
increase in liver triglycerides or lipogenic gene expression at week 39
(Supplementary figure S1), but treatment related differences were present in
tissues from female mice. Based on these results, female mice were chosen
for further study. Pilot dose finding studies indicated that free BPA in serum in
the dams and pups at PND 32 was below detectable limits. Detectable levels
of total BPA in serum of mothers and pups was 0.6-0.7 ng/ml for BPA 25.
Fig. 1A shows changes in body and liver weight between control and BPA
treated animals. BPA increased body weight by ~15% compared to control at
both ages. Liver weights were similar between treatment groups at both ages.
As compared to control, BPA significantly increase hepatic TG content at week
5 by about 33%, but not significant increase in week 39 (Fig.1B).

ORO

staining of frozen sections revealed more lipid accumulation with BPA in both
week 5 and week 39 livers as compared to respective controls.
Representative images are presented in fig.1C, and three images from each
sample in all the groups were used to quantify lipid deposits and plotted (Fig.
1D)
2.4.2 Effect of PNPP BPA exposure on expression hepatic lipogenic gene
expression in female mice at puberty (week 5) and adult (week 39) age.
The effect of PNPP BPA exposure on gene expression related to hepatic lipid
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metabolism was evaluated by real time PCR. Fig. 2 illustrates the effect of
PNPP BPA exposure on expression of transcription factors (Srebp1, Ppar-γ)
involved in regulation of hepatic lipid homeostasis as well as key enzymes
Acc, Fas and Gpat at both puberty as well as adult age of female offspring. At
week 5, except Scd, BPA induced increase in other targets measured was not
significant.

However, at week 39, Ppar-γ, Fas, Acc, and Gpat mRNA

expression was approximately doubled compared to controls (Fig. 2A, 2B).
Figures 3 and 4 depict expression of proteins in liver related to hepatic lipid
accumulation in both weeks with BPA exposure. In week 5 females, BPA
increased Ppar-γ levels in nuclear fractions by 300% compared to controls.
BPA increased pSrebp1 protein levels to two-fold compared to controls. At
week 39, significant induction in protein expression of Ppar-γ and Srebp1c
was noted (Fig 3A, 3B). At week 5, BPA increased Fas, Acc, and pAcc protein
expression by more than 135%, 200% and 135% respectively. At week 39,
BPA25 increased Fas and pAcc protein expression by 50 and 75%, but did not
significantly increase Acc levels (Fig. 4A, 4B).
2.4.3 PNPP BPA exposure enhanced Nrf2 and Nrf2-dependent protein
expression. Messenger RNA and protein expression for Nrf2, and its target
enzymes Gclc were determined (Fig. 5). Protein expression of nuclear Nrf2
and total Gclc were increased by 30% or more with BPA treatment in both
week 5 and week 39 livers.
To examine whether BPA exposure was associated with increased oxidative
stress, reduced GSH was measured in liver.

At week 39, hepatic GSH

concentration was similar between controls and BPA exposed group
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(Supplementary figure S2), indicating a lack of significant oxidative stress in
liver.
2.4.4 PNPP BPA exposure was associated with hypomethylation in
regions of the mouse Srepb-1c and Nrf2 promoters. The effect of BPA on
gene-specific promoter methylation was determined using methylated DNA
immunoprecipitation (MeDIP) using 5- methyl cytosine antibody (5-MC) and
according to published protocol (31).

Promoter sequences for lipogenic

targets were analyzed for presence of CpG site on Methprimer (University of
California, San Francisco), and these sites were checked for methylation
status. In week 5 mice, BPA decreased methylation in regions upstream of
the translational start site. BPA treated groups showed less enrichment of 5MC for Srebp1-c promoter (-231 to -346 and -1325 to -1456), Fas promoter (306 to -472 and -654 to -832) and at one promoter region checked for Nrf2 (1059 to -1168) (Fig. 6). In week 39 livers, BPA was associated with markedly
less enrichment of methylated DNA at multiple regions. With exception of
Srebp-1c promoter region from -231 to -346, other promoter regions checked
displayed a uniform decrease in the DNA methylation.
Further, a sequence of Nrf2 promoter (-1405 to -1088) containing 4 CpG sites
(CpG#1, 2, 3 and 4 respectively at -1132, -1144, -1147, -1157) was analyzed
to determine change in site-specific methylation upon BPA exposure by
pyrosequencing using bisulfide converted DNA (Table 1). In week 5, CpG#1
site is significantly less methylated in BPA treated mice as compared to
control. No change in three other CpG sites was observed. Interestingly, in
week 39, BPA significantly lower percent methylation of other CpG site
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(CpG#4). Multiple other regions of the Srebp-1 and Nrf2 promoter were also
checked, and displayed no prominent changes in DNA methylation with BPA
in week 5 and week 39 mice (Data not shown).
2.4.5 PNPP BPA exposure enhances recruitment of Nrf2 to the promoter
of lipogenic genes. In week 5 mice, BPA increased recruitment of Nrf2 to a
putative ARE binding site at -120 to -130 upstream of translational start site in
mouse Srebp-1c gene as compared to negative control (IgG) depicted
transcriptional regulation of Srebp-1c by Nrf2 upon BPA treatment.
Interestingly, this transcriptional regulation of lipogenic proteins by Nrf2 was
persistent with BPA in week 39 mice as well (Fig 7B). BPA exhibited higher
binding of Nrf2 on Srebp-1c, at same region of upstream of translation start
site in week 39 females.

Real time PCR results also showed higher

enrichment of Nrf2 on Srebp-1c promoter upon BPA treatment in both week 5
and week 39 mice (Fig 7C).
2.4.6 Effect of NRF2 Over-expression on transactivation of human Srebp1c promoter. Co-transfection of reporter genes with NRF2 increased
luciferase activity and thus significantly transactivated Srebp1c reporter
(Figure 8A) indicating the potential ARE is located in this Srebp1 promoter
region. Furthermore, treatment of HepG2 cells with known Nrf2 activators,
sulforaphane and oleanolic acid, enhanced transactivation of the Srebp-1c
promoter, supporting the presence of functional ARE in Srebp-1c promoter.

44

2.5 DISCUSSION

Using BPA as a model compound, here we provide a first evidence for Nrf2mediated environmental chemical induced lipid homeostasis alterations.
Presence of functional ARE in the Srebp-1c promoter demonstrates
involvement of Nrf2 in hepatic lipid accumulation under the influence of
chemical exposure. Moreover, persistent effects of BPA induced steatosis
pertinent of DNA hypomethylation are in agreement with published literature
that demonstrates epigenetic imprinting capabilities of BPA –reviewed by (32).
We report induction of hepatic steatosis with PNPP BPA exposure in young
and adult female mice. Our findings are consistent with a recent pediatric
study, which demonstrated higher levels of urinary BPA in females as
compared to males, with an association with NAFLD (13).

Moreover, in

human cross-sectional studies, urinary BPA levels correlated positively with
BMI more significantly in girls between 9 to 12 years of age than other age
groups, implying the sensitivity of pubertal female population to BPA (12). The
observed increased lipid level was associated with induction of mRNA and
protein expression of enzymes and transcription factors that induce hepatic
lipid accumulation. Furthermore, the findings herein have uncovered new
mechanisms for PNPP BPA-induced hepatic steatosis through promoter
hypomethylation, describing new areas of differential methylation at the Srebp1c, Fas, and Nrf2 mouse promoters, as well as describe Nrf2 enrichment at
new putative AREs in the mouse Srebp-1c promoter.
The Environmental Protection Agency and US Food and Drug Administration
published tolerable daily intake (TDI) value for BPA around 50μg/kg, and the
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exposure level chosen in current study is lower than TDI. More importantly,
published studies suggest that dose of 400μg/kg BW/day in mice resulted in
serum levels (0.5ng/ml) of unconjugated BPA much lower than amount noted
in human serum after environmental exposure (2 ng/ml) (33). In addition to
dose, timing of exposure to potential endocrine disruptors like BPA is also a
critical determinant for disease susceptibility (6, 34). Effects of fetal or
neonatal exposure of BPA are hypothesized to be as critical as adult exposure
(6, 35). As based on ‘fetal plasticity’ theory any effects that affect embryo can
remain persistent for life. In our model, female mice were exposed to BPA
during gestation and lactation. Overall, it was observed in the study herein
that BPA induced hypomethylation at some sites in the liver genome that
persisted (e.g. Srebp1c -1325 to -1456; Fas -654 to -832, -306 to -472; Nrf2 1059 to -1168), whereas methylation in other sites in the genome differed at
weeks 5 and 39. This data suggests the potential that some sites might be
persistently “marked”, whereas others are more “plastic” with the ability to be
more dynamically regulated by methylation-regulating enzymes or changes in
methyl donor content.

This observation is highly relevant to the field of

epigenetics and supports other observations of plasticity in methylation (36).
Effects at low dose, as well as exposure time dependent effects support the
notion of BPA being a “critical window of exposure” compound.
In the current study, as well as published findings (7), liver weights remained
unchanged with BPA exposure irrespective of route and time of administration
in both mice and rats. Interestingly, BPA exposed rodents exhibited evident
hepatic lipid accumulation among several studies (6, 7). A major source of
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liver lipids besides dietary consumption is de novo synthesis (37).

Our

observations herein, as well as ones from the latter studies using rodents are
supported to some degree by recent finding published associated NAFLD with
BPA exposure in children (13).

The majority of BPA exposure studies related

to NAFLD have focused primarily on disturbances lipid synthesis at the
transcriptional level. Induction of Srebp-1c and Ppar-γ in livers was observed
across all these studies, and the resulting Fas and Acc induction could be a
result of enhanced transcriptional regulation or direct action of BPA on these
enzymes. Impairment of -oxidation can also result in lipid accumulation in
liver (38).

In our study, down regulation of oxidation regulators in week 5

animals on mRNA level was observed (Supplementary figure S3); however,
effect did not remain consistent in adult animals. Further exploration of BPA
effect on lipid oxidation is needed.
Early life exposure to BPA caused persistent changes in lipogenesis that were
observed in adult even after stopping the exposure in current study. In
previous study, in utero and lactational exposure of BPA showed accumulation
of lipid in adult rat liver by induction of Srebp-1c and related genes; however
the study did not reveal the mechanism of lifelong effect of early exposure but
they postulated the epigenetic regulation of lipogenic pathway (7). In present
study, PNPP exposure of BPA did changes at lipogenic as well as Nrf2 gene
specific promoter methylation when analyzed by MedIP. Potential of BPA to
cause gene specific promoter methylation changes have also been studied in
other genes involved in insulin signaling pathway which resulted in
disturbances of adulthood glucose homeostasis (39).
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BPA induced

hypomethylation was evident in week 5 as well as week 39 animals; however,
extent of hypomethylation differed between ages. These differences in agedependent methylation patterns need further investigation. Gene and protein
expression changes in adult age also appeared more prominent in adult mice
as opposed to younger mice. Less uniform epigenetic results, associated with
less prominent changes in gene expression in week 5 animals suggest that
biological effects exerted by early life BPA exposure of a major concern in
adult population.

Moreover, lack of perfect correlation between DNA

methylation changes and gene/ protein expression changes also imply
possibility of involvement of other epigenetic mechanisms besides promoter
methylation.
BPA-mediated induction of lipid synthesis enzyme expression has been
demonstrated (6), however the upstream mechanism by which BPA imparts
this upregulation remains unknown. One potential mechanism could be via
upregulation of Nrf2 expression and regulation of lipogenic genes as
previously described (28, 40). Although most commonly studied for countering
oxidative stress, Nrf2 can be upstream regulator of adipogenesis through
Ppar-γ and Cebp-β transcriptional regulation in rodent pre-adipocytes (29, 30).
Along with adipose tissue, the role of Nrf2 in regulation of hepatic lipid
synthesis is an area under investigation. Direct in vitro exposure of BPA in
human embryonic kidney (HEK) cells induced nuclear level of Nrf2 (41).
Similarly, present study depicted induction of Nrf2 expression at mRNA as well
nuclear protein level upon PNPP exposure to BPA. With the help of ChIP
assay in our study we showed novel binding of Nrf2 on consensus ARE
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sequence on Srebp-1c promoter. Moreover, BPA exposure enhanced this
binding and hence we can infer that BPA induced expression of Srebp-1c
expression in our model is possibly mediated through Nrf2 regulation.
Transfection of Nrf2 in HepG2 cells, as well as its activation by known
chemicals oleanolic acid and sulforaphane demonstrated luciferase activity at
the Srebp-1c promoter reporter. These findings establish novel function for
Nrf2 from transcriptional regulation of hepatic denovo lipogenesis.
Overall, the present study provides the mechanistic exploration of exposure to
environment toxicants like BPA for adulthood metabolic disorders like hepatic
steatosis. Because of persistent mechanisms such as epigenetic imprinting,
exposure to environmental chemicals exerts biological effects not only based
on amount, but on the time of exposure. We addressed promoter methylation
changes caused by PNPP BPA exposure, but certainly other epigenetic
mechanisms need to be explored in detail as well, to obtain more
comprehensive

picture

regarding

these

persistent

effects.

Histone

modifications or microRNA changes (42, 43) that are known to be affected in
or known to cause NAFLD also need elucidation in regard to environmental
toxicity. Also, considering ubiquitous expression and function of Nrf2, its role
in environmental toxicity is vital to study.

Here we provide evidence for

binding of Nrf2 on promoters of lipogenic genes, and the binding increases
with BPA exposure. In conclusion, PNPP BPA induced lipogenic effects were
demonstrated in this study, and detailed epigenetic and Nrf2-mediated
mechanisms were elucidated.
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2.6 FIGURE LEGENDS
Figure 1: Perinatal peripubertal (PNPP) exposure to bisphenol A affects
body weight and hepatic lipid accumulation in female CD1 mice. A) Body
weight and liver weight.

Statistical differences between the groups were

determined by Student’s t-test. Asterisk (*) represents significant difference in
weights between BPA treated and vehicle treated animals of same age group
(p≤0.05).

B) Hepatic triglyceride (TG) quantification. C) Oil red o (ORO)

staining of lipids in the liver tissue. Representative images are displayed in
200X magnification. D) Quantification of oil red staining density from all the
samples.
Figure 2: Perinatal peripubertal (PNPP) exposure to bisphenol A
increases mRNA expression of lipogenic targets in livers of female CD1
mice (A. Week 5; B. Week 39). mRNA was quantified using real time
polymerase chain reaction (RT-PCR) using primers specific for sterol
regulatory element binding protein 1c (Srebp-1c), peroxisome proliferator
activated receptor gamma (Ppar-γ), fatty acid synthase (Fas), acetyl coA
carboxylase (Acc), and glycerol-3-phosphate acetyl transferase (Gpat). Raw
data was normalized to respective control expression, and statistical
differences between the groups were analyzed by Student’s t-test. Asterisk (*)
represents significant difference in expression between BPA treated and
control animals (p≤0.05).
Figure 3: Perinatal peripubertal (PNPP) exposure to bisphenol A
increases protein expression of lipogenic transcription factors in livers
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of female CD1 mice (A. Week 5; B. Week 39). Nuclear proteins were
detected for expression using specific antibodies for peroxisome proliferator
activated receptor gamma (Ppar- ), sterol regulatory element binding protein
1c (Srebp-1c), and phosphorylated Srebp-1c. The blots were developed using
autoradiography and the mean blot intensity is presented in percent protein
expression format. Statistical differences between the groups were analyzed
by Student’s t-test. Asterisk (*) represents significant difference in expression
between BPA treated and control animals (p≤0.05).
Figure 4: Perinatal peripubertal (PNPP) exposure to bisphenol A
increases protein expression of lipid synthesis enzymes in livers of
female CD1 mice (A. Week 5; B. Week 39). Protein expression was
quantified by western blot using specific antibodies for fatty acid synthase
(Fas), acetyl CoA carboxylase (Acc) and phosphorylated Acc. The blots were
developed using autoradiography and the mean blot intensity is presented in
percent protein expression format. Statistical differences between the groups
were analyzed by Student’s t-test.

Asterisk (*) represents significant

difference in expression between BPA treated and control animals (p≤0.05).
Figure 5: Perinatal peripubertal (PNPP) exposure to bisphenol A and
nuclear factor E2 related factor 2 (Nrf2) signaling in livers of female CD1
mice. A) Nrf2 and its target gene glutamate cysteine ligase (Gclc) expression
in livers of week 5 animals. mRNA expression was quantified using real time
polymerase chain reaction (RT-PCR) using primers specific for Nrf2 and Gclc.
B) Protein expression of nuclear Nrf2 and Gclc.

Protein expression was

quantified by western blot using specific antibodies for Nrf2 and glutamate
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cysteine ligase (Gclc). The blots were developed using autoradiography and
the mean blot intensity is presented in percent protein expression format. C)
Nrf2 and Gclc mRNA expression in week 39 animals. D) Protein expression of
nuclear Nrf2 and Gclc in week 39 animals. Statistical differences between the
groups were analyzed by Student’s t-test. Asterisk (*) represents significant
difference in expression between BPA treated and control animals (p≤0.05).
Figure 6: Effect of Perinatal peripubertal exposure of BPA on promoter
methylation of Srebp-1c, Fas and Nrf2 analyzed by methylated DNA
immunoprecipitation

(MeDIP).

Genomic

DNA

(6μg)

was

sonicated,

denatured and subjected to immunoprecipitation by using 5-methyl cytosine or
IgG antibody. Agarose beads were used to recover enriched methylated DNA.
After purification real time PCR were performed to amplify methylated DNA
fragments using different primers covering promoter sequences containing
CpG sites. CpG sites in Promoter sequences of Srebp-1c, Fas and Nrf2 (A, B
and C respectively) up to 2 kb upstream of translational start site were
analyzed to check methylation effects of PNPP BPA. Results are plotted in
the form of fold enrichment.
Figure 7: Chromatin immunoprecipitation of nuclear factor E2 related
factor 2 (Nrf2) on Srebp-1c gene promoter. A. Nrf2 recruitment on promoter
of Srebp-1c (Schematic representation). Liver tissues of BPA treated both
young as well as adult female offsprings mice were homogenized with PBS.
Homogenate was cross-linked by adding 1% formaldehyde for 10 min and
crosslinking was stopped by 125 mM glycine solution. Crosslinked chromatin
was sheared and immunoprecipitated with anti-Nrf2 or anti-rabbit IgG antibody
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overnight at 4°C with rotation. Antibody-chromatin complex was recovered by
adding preblocked Dynabeads Protein A.

After reverse crosslinking and

purification Nrf2 and IgG precipitated DNA were subjected to B. End point
PCR, C. Real time PCR amplification by using primers as enlisted in
supplementary table S3, which covers putative ARE consensus sequence on
promoter of Srebp-1c.

Results are plotted in the form of fold enrichment

compared to negative control.
Figure 8: Nrf2 mediated transactivation of human Srebp-1 in vitro. A.
Transcription factor NRF2 expression plasmid were transiently co-transfected
with the Srebp-1 promoter luciferase reporter constructs (-1.5kb) or pGL3
basic, in HepG2 cells for 24hrs in serum free DMEM media. Luciferase activity
was measured as relative firefly/renilla luciferase and was recorded as relative
light units data are presented as mean fold change ± SEM.

Statistical

differences between the groups were analyzed by one-way ANOVA followed
by Duncan’s posthoc test.

Asterisk (*) represents significant difference in

expression between BPA treated and control animals (p≤0.05). B. Effect of
Nrf2 activators on Srebp-1c directed reporter gene activity: Srebp-1c promoter
luciferase reporter constructs or pGL3 basic were transiently transfected into
HepG2 cell. After 24 hrs of transfection HepG2 cell were treated with the
oleanolic acid (50uM) and sulforaphane (10uM) along with DMSO (0.05%) for
12hrs. Luciferase activity was measured using a commercial kit.
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2.9 TABLES:
Table 1: Site specific methylation (%) of 4 CpG sites for Nrf2 promoter
upon PNPP BPA exposure in week 5 and 39 age of mice. Values were
adjusted to a standard curve of control DNA (ranging between 0 and 100%)
run for each CpG site on the corresponding experimental plate for each
sample. Asterisk * represents statistically significant difference between
control and BPA treated groups (p<0.05).

Week 5

CpG #1

CpG #2

CpG #3

CpG #4

Control

20.47 ± 2.44

7.46 ± 1.62

2.39 ± 0.90

8.16 ± 1.88

BPA

11.61 ± 1.74*

6.52 ± 1.47

5.16 ± 2.24

10.84 ± 2.67

Week 39

CpG #1

CpG #2

CpG #3

CpG #4

Control

13.26 ± 0.61

6.44 ± 1.23

4.38 ± 1.74

19.03 ± 0.9

BPA

15.70 ± 3.30

6.49 ± 0.95

2.44 ± 1.26

7.64 ± 2.42*
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Table 2: PCR conditions for Pyro-Sequencing
Primer/sequence to analyze
Forward PCR primer

Nrf2 Assay
GTAGTTAAAGAAGTATGTTTGGGAATGA

Reverse PCR primer

Biotin-TATAATCTCATAAAACCCCACCTCTC

Sequencing primer (5’ to 3’)

ATAATAAGAATTATATTAAAGGG

Amplicon length

318

Temperature

58

Number of cycles

45
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2.12 SUPPLEMENTARY DATA:
Supplementary figure S1: Effect of perinatal peripubertal (PNPP) BPA
exposure on hepatic triglyceride (TG) and mRNA expression in male
offsprings at week 39 of age. A. TG quantification. B. Gene expression of
lipogenic targets. Raw data was normalized to respective control expression,
and statistical differences between the groups were analyzed by Student’s ttest. Asterisk (*) represents significant difference in expression between BPA
treated and control animals (p≤0.05).
Supplementary figure S2: Glutathione (GSH) levels in the livers of week
39 mice exposed to PNPP BPA. Liver tissue was homogenized and the GSH
was quantified by commercial kit from Promega (Madison, WI). Raw data was
normalized to respective control expression, and statistical differences
between the groups were analyzed by Student’s t-test.
Supplementary figure S3: Perinatal peripubertal (PNPP) exposure to
bisphenol A increases mRNA expression of -oxidation targets in livers
of female CD1 mice (A. Week 5; B. Week 39). Total RNA was extracted
from liver tissue by phenol-chloroform extraction using TRIzol® reagent.
Messenger RNA was converted to cDNA and subsequently quantified using
real time polymerase chain reaction (RT-PCR) using primers specific for
peroxisome proliferator activated receptor alpha (Ppar-α), cytochrome P450
4a10 (Cyp4a10), carnitine palmitoyltransferase 1a (Cpt1a). Raw data was
normalized to respective control expression, and statistical differences
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between the groups were analyzed by Student’s t-test. Asterisk (*) represents
significant difference in expression between BPA treated and control animals
(p≤0.05).
Supplementary table S1: Primer sequence for quantitative RT-PCR
Supplementary table S2: List of primary and secondary antibodies for
western blot and chromatin immunoprecipitation
Supplementary table S3: Primer sequence for amplification of DNA from
chromatin immunoprecipitation
Supplementary

table

S4:

Primer

immunoprecipitation output amplification
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sequence

for

Methylated

DNA
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Supplementary table S1: Primer sequence for quantitative RT-PCR

Gene

Forward

Reverse

Srebp1c

GCAGCCACCATCTAGCCTG

CAGCAGTGAGTCTGCCTTGAT

Ppar-γ

CTCTGTTTTATGCTGTTATGGGTGA

GGTCAACAGGAGAATCTCCCAG

Fas

GGAGGTGGTGATAGCCGGTAT

TGGGTAATCCATAGAGCCCAG

Acc

GATGAACCATCTCCGTTGGC

GACCCAATTATGAATCGGGAGTG

Gpat

ACAGTTGGCACAATAGACGTTT

CCTTCCATTTCAGTGTTGCAGA

Nrf2

TCTTGGAGTAAGTCGAGAAGTGT

GTTGAAACTGAGCGAAAAAGGC

Keap1

CTGCCCAATTCATGGCTCACA

CTTAGGGTGGATGCCTTCGAT

Nqo1

AGGATGGGAGGTACTCGAATC

TGCTAGAGATGACTCGGAAGG

Gclc

GGGGTGACGAGGTGGAGTA

GTTGGGGTTTGTCCTCTCCC

B2M

TTCTGGTGCTTGTCTCACTGA

CAGTATGTTCGGCTTCCCATTC
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Supplementary table S2: List of primary and secondary antibodies for
western blot and chromatin immunoprecipitation assay

Antibody
name

Primary/
Secondary

Protein
fraction

Application

Source

Gapdh/ Bactin

Primary

Total,
Membrane

WB

Cell Signaling
Tech

Acc-1

Primary

Total

WB

Cell Signaling
Tech

pAcc-1

Primary

Total

WB

Cell Signaling
Tech

Ppar-γ

Primary

Total

WB

Cell Signaling
Tech

Primary

Total

WB

Srebp1c
ChIP
p-Srebp1c
Primary

Total

WB

Nuclear

WB

Nrf2

Active Motif
Active Motif
Cell Signaling
Tech
Gift from Dr.
Schmidt’s lab

ChIP

Cell Signaling
Tech

Gclc

Primary

Total

WB

Abcam

Anti-mouse

Secondary

-

WB

Sigma Aldrich

Anti-rat

Secondary

-

WB

Sigma Aldrich, St
Louis, MO

Anti-rabbit

Secondary

-

WB

Sigma Aldrich, St
Louis, MO
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Supplementary table S3: Primer sequence for ChIP

Promoter

Predicted ARE
(Considering
Coding start site
as +1)

Forward

Reverse

Srebp 1c

-120 to -130

TAGGCGAGCTGTCAGGAT

TCTCGGCCAGTGTCTGT
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3.1 ABSTRACT:
PFOS is a chemical of nearly ubiquitous exposure in humans. Recent
studies have associated PFOS exposure to adipose tissue-related effects.
The present study was to determine whether PFOS alters the process of
adipogenesis in mouse and human preadipocytes and regulates insulinstimulated glucose uptake. In murine-derived 3T3-L1 preadipocytes, PFOS
enhanced hormone-induced differentiation to adipocytes and adipogenic
gene

expression,

increased

insulin-stimulated

glucose

uptake

at

concentrations ranging from 10 to 100 M, and enhanced Glut4 and Insulin
receptor substrate-1 expression. Nrf2, Nqo1 and Gclc were significantly
induced in 3T3-L1 cells treated with PFOS, along with a robust induction of
antioxidant response element (ARE) reporter in mouse embryonic
fibroblasts isolated from ARE-hPAP transgenic mice by PFOS treatment.
Chromatin immunoprecipitation assays further illustrated that PFOS
increased Nrf2 binding to ARE sites in mouse Nqo1 promoter, suggesting
that PFOS activated Nrf2 signaling in murine-derived preadipocytes.
Additionally, PFOS administration in mice (0.1mg/kg BW/day) induced
adipogenic gene expression and activated Nrf2 signaling in epididymal
white adipose tissue. Moreover, human visceral preadipocytes illustrated
that PFOS (5 and 50

M) promoted adipogenesis and increased cellular

lipid accumulation. It was observed that PFOS increased Nrf2 binding to
ARE sites in association with Nrf2 signaling activation, induction of Ppar78

and Cebpα expression, and increased adipogenesis. This study points to a
potential role PFOS in dysregulation of adipose tissue expandability, and
warrants further investigations on the adverse effects of persistent
pollutants on human health.

Key words: PFOS, Nrf2, Ppar- , adipogenesis, glucose uptake, ARE
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3.2 INTRODUCTION
Perfluorooctanesulfonate (PFOS) and Perfluorooctanoic acid (PFOA) are
organic fluoroalkyl chemicals widely used in industrial and consumer
applications as powerful surfactants and building material components, as
they are stable at high temperature and nonflammable (Olsen et al., 2005).
These two chemicals have been detected worldwide in the environment,
including drinking water (Skutlarek et al., 2006), atmosphere air (Shoeib et
al., 2005), soil, sediments (Boulanger et al., 2005), and even the wildlife in
the Antarctic Pole (Giesy and Kannan, 2001).

Average human serum

PFOS and PFOA content has decreased between 2000 and 2005 due to
the phase out of perfluorooctanesulfonyl-fluoride (POSF, C8F17SO2F)based materials by the primary global manufacturer, 3M Company, in May
2000 (Olsen et al., 2007b), but the related health effects still remain a
concern. Although have been banned in United States and Europe, PFOS
and PFOS-related chemicals are still currently produced in China.
Importantly, PFOS and PFOA are readily absorbed and poorly eliminated
from humans.

Increased renal absorption via transport mechanisms is

suspected to be the mechanism that contributes to the relatively long
serum half-lives observed in humans (Olsen et al., 2007a), which has been
estimated to 5.4 (PFOS) and 3.8 (PFOA) years. Because of its persistence
in the body and presence in populations across the world, it is important to
assess potential health effects.

Liver is the major organ affected by
80

exposure of PFOS in animal model, as it is known to deposit in liver and is
associated with increased liver weight in rats, mice, and monkeys (Chang
et al., 2012; Wan et al., 2012). Exposure of PFOS has been shown to
induce further undesirable effects, such as increased hepatic lipid
accumulation along with significant induction of CD36 and lipoprotein lipase
(Lpl) expression, which resulted in disturbance of lipid metabolism and
excessive fatty liver (Wan et al., 2012). In addition, dietary administration
of PFOS in mice (0.005%, w/w) for 10 days reduced serum cholesterol and
triglycerides levels, and induced a moderate hepatomegaly (Qazi et al.,
2010). More recent publications reported that exposure of PFOS altered
expression of genes mainly involved in lipid modulation, energy metabolism,
reproduction, hormone regulation, suggesting a role for PFOS in regulating
lipid metabolism and development (Hu et al., 2005; Hagenaars et al., 2008).
The observed hepatomegaly that results from PFOS administration is due
to peroxisome proliferator-activated receptor (Ppar) activation (Takacs and
Abbott, 2007; Bjork and Wallace, 2009). Rosen et al. also reported that
PFOS may modulate various gene expression related to lipid metabolism,
inﬂammation,

and

xenobiotic

metabolism

via

Ppar-

independent

mechanisms, such as the modest activation of constitutive and rostane
receptor (CAR) and Ppar- signaling pathway (Rosen et al., 2010). And
PFOA was reported to induce various xenobiotic metabolism genes, which
were under the control of CAR and transcription factor of nuclear factor
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erythoid 2-related factor 2 (Nrf2) (Rosen et al., 2008). However, PFOS
effects on adipogenesis and white adipose tissue expansion is still
unknown.
Adipogenesis is a process involving sequential coordinated gene induction
(Rosen and Spiegelman, 2000). CCAAT/enhancer-binding protein (Cebp)
and Cebp-

induce the expression of Ppar- , which activates Cebp- ,

and these two transcriptional factors can work in concert to maintain the
differentiated status.

Gain-of-function experiments that forced Ppar-

and/or in combination with potential agonists demonstrated that nonadipogenic, fibroblast cells can be transdifferentiated to adipocytes (Wu et
al., 1995). Emerging data points to new regulators of Ppar- expression,
such as transcription factor of Nrf2, regulated lipid metabolism and the
process of adipogenesis (Shin et al., 2007; Pi et al., 2010). Classically,
Nrf2 binds to antioxidant-responsive elements (ARE), induces expression
of a battery of detoxification and antioxidant genes to counter cellular
electrophilic and oxidative stress (Kensler et al., 2007; Klaassen and
Reisman, 2010). Pi et al. reported that an ARE element exists in mouse
Ppar-

promoter, and loss of Nrf2 reduced Ppar-

expression and

prevented the process of adipogenesis in 3T3-L1 preadipocytes (Pi et al.,
2010). This work provided a link between Nrf2 and adipogenesis. Other
studies have demonstrated that too much Nrf2 activation can also perturb
adipogeneis.

An early study by Kensler described Nrf2 prevented
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adipogenesis via modulating Aryl hydrocarbon receptor Signaling (Shin et
al., 2007). Our previous results demonstrated that enhanced Nrf2 activity
via Keap1-knockdown inhibited white adipose tissue expansion and the
adipocyte differentiation, suggesting the Nrf2-independent mechanism
involved in Keap1-knockdown (Xu et al., 2012).

Additionally, PFOS

increased cellular reactive oxygen species (ROS) content, induced the
antioxidant signaling of Nrf2 and Heme oxygenase-1 (Ho-1) expression
levels, suggesting the relationship between PFOS administration and Nrf2
signaling activation (Shi and Zhou, 2010) from in vitro study.
To evaluate the effect of PFOS on adipogenesis, and further explore its
effect on regulating white adipose tissue expansion and the development of
obesity, 3T3-L1 preadipocytes were induced to differentiation to adipocytes
with the presence of PFOS. The cellular lipid content and adipogenic gene
expression was evaluated. Additionally, glucose uptake was determined in
the mature adipocytes with PFOS administration. Lastly, PFOS-induced
adipogenic effects were also evaluated in a whole animal model with daily
PFOS administration and in human visceral preadipocytes. The current
study demonstrates that PFOS induces Nrf2 activation in association with
promoting Ppar- and Cebp- signaling, and induction of adipogenesis that
increases lipid accumulation in 3T3-L1 preadipocytes.

Moreover, pro-

adipogenic effects were observed in human visceral preadipocytes
exposed to PFOS.
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3.3 MATERIALS AND METHODS
3.3.1 Chemicals. Heptadecaperfluorooctanesulfonic acid potassium salt
(#77282, PFOS), insulin (#I6634), dexamethasone (#D4902, DEX)
isobutylmethylxanthine (#I5879, IBMX), and Oil Red O (#O0625) were got
from Sigma-Aldrich (St. Louis, MO). Ethanol, methanol, and isopropanol,
MTT solution and other chemicals without specific illustration were got from
Thermo Fisher Scientific Inc. (Waltham, MA)
3.3.2 Animals and PFOS administration.

10-week-old male C57BL/6

mice weighing approximately 30 grams were purchased from Charles River
Laboratories (Wilmington, MA). The mice were housed under a controlled
temperature (22-25 °C) with relative humidity (30-70%), lighting (12 hrs,
light-dark cycles) environment and acclimated for 5 weeks on the standard
rodent chow to allow for additional weight gain. At 15 weeks of age, the
mice were then fed a purified rodent chow (AIN-93G Growth Purified Diet,
TestDiet, St. Louis, MO).

At 21 weeks of age, mice (n=8) were

administered water as vehicle (Veh) via oral gavage (5mL/kg) or PFOS
(0.1mg/kg, 5mL/kg) for 6 weeks.

Body weight and food intake were

monitored daily and recorded. Epididymal white adipose tissue (WAT) was
collected, snap frozen with liquid nitrogen, and stored at -70°C until
analysis.

All procedures were conducted in accordance with the NIH

Guidelines for the Care and Use of Laboratory Animals and were approved
by the University of Rhode Island Animal Care and Use Committee.
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3.3.3 Acute cytotoxicity assay. A minimum of 5 replicates of 7,500 3T3L1 preadipocytes per well were plated in 96-well plates and allowed to
adhere to the plate for approximately 12 hrs, at which time the media was
removed and replaced with fresh media containing varying concentrations
of PFOS in DMSO (1nM, 5nM, 10nM, 100nM, 500nM, 1 M, 5 M, 10 M,
50 M, 100 M). Cells were subsequently incubated for an additional 48
hrs. Then 20 L MTT solution (5 mg/mL in PBS) was added and the plate
was incubated for another 3 hrs. The supernatant was removed carefully
and 150

L MTT solvent (4 mM HCl, 0.1% NP-40 in isopropanol) was

added to each well. The plate was covered with foil and agitated on an
orbital shaker for 15 mins. The cell viability was determined by measuring
the absorbance at 590 nm with 620 nm as reference filter. Relative cell
viability (%) was displayed using vehicle (0.1% DMSO)-treated samples as
a standard.
3.3.4 Cell culture and 3T3-L1 pre-adipocyte differentiation.

Mouse

3T3-L1 (ATCC® CL-173TM) preadipocytes were obtained from ATCC
(American Type Culture Collection, Manassas, VA, USA) and maintained in
high-glucose DMEM medium supplemented with 10% fetal bovine serum
(FBS). 3T3-L1 pre-adipocyte differentiation was induced according to the
protocol described previously (Shin et al., 2007; Xu et al., 2012). Briefly, 2
days post 100% confluence, 3T3-L1 preadipocytes were stimulated to
differentiation to adipocytes in a standard adipogenic differentiation
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medium (DMEM containing 10%FBS, 10 g/mL insulin, 1 M DEX, 0.5mM
IBMX), which was considered Day 0. Cells were cultured in the latter media
for Days 0-3 and then cultured in DMEM containing 10%FBS and 10 g/mL
insulin for the remaining days. Media was refreshed every 2 days. Cell
treatment and corresponding assay were described as Figure 1A.
3.3.5 Human visceral preadipocytes culture and induction to
adipocytes. PoieticsTM Human visceral preadipocytes (Donor #: 24711;
Lot #:0000313366; Cat #: PT-5005) were obtained from Lonza (Lonza
Walkersville, Inc., Walkersville, MD) and maintained in PBM-2 media
according to the manufacturer’s instructions.
plated at 8,700 cells per well.

The preadipocytes were

Cells were induced to differentiation to

adipocytes by switching with the differentiated media of PBM-2
supplementing

with

dexamethasone,

isobutylmethylxanthine

and

insulinSingleQuotsTM 24 hrs post 100% confluence and keep in the same
media for the next 11 days. Cells were treated with DMSO (0.1%) or PFOS
(5 or 50 M) in quadruplicates.

Oil red O was used to image the lipid

droplets. The cellular lipid was purified via isopropanol extraction and the
lipid content was quantified spectrophotometrically at what 520 nm. Cell
treatment and corresponding assay were described as Figure 1B.
3.3.6 RNA isolation and quantitative real-time PCR.
isolated

using TRIzol

reagent

(Invitrogen,

CA)

Total RNA was

according

to

the

manufacturer’s instructions. One microgram of total RNA was converted to
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cDNA and mRNA levels were quantiﬁed by quantitative real-time PCR
using a Roche LightCycler 480 System (Roche Applied Science,
Mannheim, Germany). SYBR green chemistry was used and relative target
gene expression was normalized to 18S rRNA. The primers used are listed
in Supplementary Table 1.
3.3.7 Oil Red O staining.

3T3-L1 preadipocytes or human visceral

preadipocytes were induced to differentiation to adipocytes.

The

supernatant was removed and cell layer was washed twice with 2 mL icecold PBS. Cells were fixed with 10% formalin at 4°C for 30 mins, then
stained with Oil Red O solution (six parts Oil Red O stock solution [0.5% Oil
Red O in 100% isopropanol] and four parts H2O) for 60 mins. Cells were
counterstained with hematoxylin and mounted in glycerin jelly (Carolina
Biological Supply Company, Burlington, NC).
3.3.8 Measurement of triglycerides in 3T3-L1 preadipocytes. 3T3-L1
preadipocytes plated on 60-mm dishes were induced to adipocytes for 8
days. Lipids were extracted according to a previous protocol (Xu et al.,
2012).

Triglycerides content were determined with reagent kits (Pointe

Scientific,

Inc,

MI),

and

the

absorbance

was

measured

spectrophotometrically at 520 nm. Relative triglycerides content (%) was
displayed using differentiation medium containing 0.1% DMSO - treated
cells as a standard.
3.3.9 Glucose uptake assay.

Glucose uptake in 3T3-L1 mature
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adipocytes was measured by using 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)
amino]-2-deoxy-d-glucose (2-NBDG) according to the manufacturer’s
instructions (Cayman Chemical Company, MI).

In brief, 3T3-L1

preadipocytes plated on 96-well fluorescent plates were induced to
adipocytes as described above. At Day 11, cells were washed with PBS
and then treated with serum-free DMEM containing PFOS (0 - 100 M) or
DMSO (0.1%) for 5 hrs. Then cells were washed with sterilized PBS for 3
times, and stimulated with 100 nM insulin for 20 mins in KRPH buffer (20
mM HEPES, 5 mM KH2PO4, 1 mM MgSO4, 1 mM CaCl2, 136 mM NaCl,
and 4.7 mM KCl, pH 7.4) with the presence of PFOS or DMSO,
respectively. Glucose uptake was initiated by the addition of 100 μg/mL 2NBDG to each well.

The fluorescence activity was monitored at an

excitation wavelength of 485 nm and an emission wavelength of 535 nm.
At least eight replicates for each dosage was performed. Relative glucose
uptake was displayed using vehicle-treated group as a standard.
3.3.10 hPAP induction assay.

Mouse embryonic fibroblast (MEF)

differentiation to adipocytes was performed as described elsewhere (Shin
et al., 2007; Xu et al., 2012). MEFs were isolated from 13.5- to 15.5-d post
coital mouse embryos from ARE-hPAP transgenic mice, then cells were
cultured in DMEM supplemented with 10% FBS in 10 cm culture dishes
(Johnson et al., 2002). MEFs were collected and cultured in 6-well plate, 2
days post of 100% confluence, cells were switched to differentiated media
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with DMEM containing 10% FBS, 10
IBMX (Day 0).

g/mL insulin, 1

M DEX, 0.5 mM

Three days later, cells were switched to media only

containing 10% FBS and 10 μg/mL insulin for the remaining days. And four
days post differentiation, total RNA was extracted and the relative mRNA
levels of hPAP were measured using quantitative real-time PCR.

The

detailed design was described as Figure 1C.
3.3.11 Chromatin Immunoprecipitation (ChIP) assay. 3T3-L1 cells were
induced to adipocytes as described above. Two days post differentiation to
adipocytes, cells were harvested and the Chip assay was performed
according to the manufacturer’s instructions (Active Motif, Carlsbad, CA).
Equal amount of sheared chromatin DNA (15 g) was incubated with antiNrf2 antibody (Cell Signaling, Danvers, MA) or IgG as negative control
overnight at 4°C. A portion of sheared chromatin DNA was preserved as
input (10 L). Purified DNA was PCR-amplified for 35 cycles (30 s at 94 °C,
30 s at 59 °C, and 30 s at 72 °C) with the primers that cover putative AREs
sequences in mouse Nqo-1 promoter.
(Forward: 5'-GCAGTTTCTAAGAGCAGAACG-3')
(Reverse: 5'-GTAGATTAGTCCTCACTCAGCCG-3')
3.3.12 Statistical Analysis. Quantitative data were presented as average
± SE. Statistic differences were determined by a one-way ANOVA followed
by a Duncan’s Multiple Range post hoc test.
P<0.05 were considered significant.
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All statistical tests with

3.4 RESULTS:
3.4.1 PFOS induces adipogenesis in 3T3-L1 preadipocytes. In order to
explore the association of PFOS exposure and adipocyte differentiation, we
determined the effect of PFOS concentrations on 3T3-L1 pre-adipocyte
viability. No overt toxicity was observed at <50 M in the current study
(Figure 1D). 3T3-L1 preadipocytes were differentiated to adipocytes in the
presence of differentiated cocktail with or without PFOS.

Oil Red O

staining of mature lipid-containing adipocytes at Day 8 was performed to
evaluate PFOS effects on adipogenesis. Figure 2A illustrates that high
concentrations of PFOS (1-100 M) increased lipid accumulation in 3T3-L1
adipocytes compared to vehicle-treated group (Figure 2A).

However,

staining was similar between vehicle- and PFOS-treated groups treated
with concentrations less than 1 M (1-500nM), except there was lower lipid
content at the dosage of 5nM (Figure, 2B, data not shown). Similar to the
observed staining, higher PFOS concentrations (1-50 M) increased
triglyceride content in 3T3-L1 adipocytes by more than 20% above control,
but this effect was not observed with the relatively lower PFOS
concentrations (1-100 nM) (Figure 2B). The data suggest that PFOS has
the potential to potentiate induction of mouse preadipocyte differentiation to
mature adipocytes and promote lipid accumulation.
3.4.2 PFOS increases adipogenic gene expression in 3T3-L1
preadipocytes. The underlying molecular mechanisms for PFOS function
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on adipogenesis were evaluated. 3T3-L1 preadipocytes were induced to
adipocytes with PFOS administration for continuous 3 days, total RNA was
extracted and the relative mRNA levels of genes related with adipogenesis
of Cebp- , Ppar- , Fabp4 and Lpl were determined. There is no significant
difference for these four genes expression between vehicle- and PFOStreated groups at Day1. After induction to adipocytes for 3 days (Day3),
Cebp-α, Ppar- , Fabp4 and Lpl were significantly induced in both groups;
with induction being significantly higher in PFOS-treated adipocytes than
vehicle-treated group (increased by 32.2-, 14.2-, 8.6-, and 19.7-fold,
respectively), suggesting PFOS increased adipogenic gene expression,
which may contribute to the increased adipogenesis (Figure 3A).
Additionally, the mRNA levels of Nrf2 and two target genes, Nqo1 and Gclc
were determined. After 3 days of induction to adipocytes (Day 3), PFOS
significantly increased Nrf2, Nqo1 and Gclc mRNA levels in 3T3-L1
adipocytes than vehicle-treated group by more than 15-fold, suggesting
that PFOS has the potential to activate Nrf2 signaling in preadipocytes
(Figure 3B).
3.4.3 PFOS promotes insulin-stimulated glucose uptake in 3T3-L1
adipocytes.

In order to assess the metabolic consequence of PFOS

treatment in 3T3-L1 preadipocytes, insulin-stimulated glucose uptake were
monitored in vehicle- and PFOS-treated adipocytes.

After 3T3-L1

preadipocytes were differentiated to adipocytes for 10 days, cells were
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exposed to PFOS for 5 hrs, then 2-NBDG was added, and the fluorescence
activity was monitored. There was no significant difference between the
low dose PFOS treatments (1 and 5

M) and vehicle-treated group.

However, insulin-stimulated glucose uptake was significantly higher in
PFOS-treated at the concentration of 10 M than vehicle-treated group (by
26%).

And a dose-dependent increase of glucose uptake by PFOS-

treatment was observed, with the highest induction being at the dosage of
100

M (61.0% higher than vehicle) (Figure 4A). The gene expression

related to insulin signaling and glucose metabolism was monitored. Low
dose PFOS treatment (1 M) did not affect Ppar- , Srebp-1c, Glut4, Irs-1,
and Insr gene expression. However, treatment with 10 or 50

M PFOS

increased Ppar- , Srebp-1c, Glut4 and Irs-1 expression compared to
vehicle-treated group, but with similar Insr expression between vehicle- and
PFOS-treated groups (Figure 4B). It was hypothesized that in the early
induction process, PFOS might induce the antioxidant response, then
leading to Nrf2 activation that augmented Ppar- induction (Shi and Zhou,
2010).

PFOS (1

M) did not induce Nrf2 or Nqo1 expression, but

expression was induced by about 30% in cells treated with 10 and 50 M
PFOS, suggesting the potential role of PFOS activating Nrf2 signaling in
mature adipocytes (Figure 4C).
3.4.4 Adipogenic gene expression and Nrf2 signaling is increased in
white adipose tissue from mice administered PFOS.
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C57BL/6 male

mice were administered PFOS for 6 weeks (0.1mg/kg BW/day) and the
transcript levels corresponding to adipogenesis and Nrf2 signaling were
measured in epididymal WAT. PFOS significantly increased the expression
of adipogenic genes, including Cebp- α, Ppar- , Fabp4 and Lpl in WAT (by
66.4%, 93.2%, 73.3%, and 67.6%). Srebp1c and Insr, related with insulin
signaling, were significantly induced after PFOS administration (by 67.2%
and 59.7%), along with the increasing tread of Glut4 and Irs-1 expression
(by 44.1% and 25.9%) (Figure 5A).

Additionally, PFOS significantly

induced Nrf2, Nqo1 and Gclc mRNA levels (by 97.2%, 173.0% and 87.3%),
suggesting enhanced Nrf2 signaling in WAT of mice administrated with
PFOS. Expression of Ho-1, Multidrug resistance-associated protein (Mrp)
2,

Mrp4,

UDP-glucuronosyltransferase

(Ugt)

1a6,

and

Superoxide

dismutase-1 (Sod-1), which are highly associated with Nrf2 signaling
(Thimmulappa et al., 2002; Dreger et al., 2009), were increased in the
current study. PFOS decreased Cytochrome P450, family 7, subfamily A,
polypeptide 1 (Cyp7a1) by 78.5% after PFOS treatment, which is
consistent with the previous study (Chang et al., 2009).
3.4.5 PFOS increased lipid accumulation in differentiated human
visceral preadipocytes.

Human visceral preadipocytes were obtained

and differentiated to adipocytes, and cellular lipid content was evaluated by
Oil red O staining. Eleven days post-differentiation, PFOS (5 and 50 M)
significantly increased staining in mature adipocytes (Figure 6A).
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Furthermore, the stain was extracted and quantified spectrophotometrically.
Figure 6B illustrates that PFOS increased staining in adipocytes by 48% at
5 M and 40% at 50 M, suggesting PFOS may increase adipogenesis in
human visceral preadipocytes, contribute to enhance lipid accumulation in
PFOS-treated group (Figure 6B).
3.4.6 PFOS increases Antioxidant Response Element activity and
enhances Nrf2 enrichment at the ARE element in mouse Nqo1
promoter. Some recent work indicates that the Nrf2 pathway is inducible
in MEFs and adipose tissue (Shin et al., 2007; Xu et al., 2012). In order to
determine whether PFOS induces Nrf2 signaling and might increase
adipogenesis via the Nrf2 signaling pathway, MEFs from ARE-hPAP
transgenic mice (Johnson et al., 2002) were isolated and differentiated to
adipocytes with or without PFOS for 4 days. Next, hPAP mRNA levels
were measured by quantitative real-time PCR. PFOS treatment (50

M)

doubled hPAP mRNA levels compared to vehicle controls (Figure 7), highly
suggesting

PFOS

increased

ARE

binding

activity

(Figure

7A).

Furthermore, to determine whether the increased ARE binding was via the
increased Nrf2 binding in PFOS treatment, Chip assay was carried out.
Figure 7B and 7C illustrate that two days into differentiation, PFOS
increased Nrf2 binding to ARE sites in mouse Nqo1 promoter (by 31%),
suggesting that Nrf2 binding was increased after PFOS treatment during
the differentiation process (Figure 7B, 7C).
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3.5 DISCUSSION:
PFOS has been manufactured for over 60 years. Epidemiological studies
and recent research with PFOS primarily focuses on widespread exposure
(Giesy and Kannan, 2001; Olsen et al., 2005), hepatic effects in humans
(Nelson et al., 2010), primates (Chang et al., 2012) and rodents (Wan et
al., 2012), and metabolic perturbations (Wan et al., 2012). However, PFOS
effects on adipogenesis or adipocyte health is largely undescribed, yet is of
growing concern because of the growing population of obese people
worldwide. In the current study, we demonstrated that PFOS augmented
adipocyte differentiation, increased the expression of key transcription
factors of Ppar- and Cebp- involved in adipogenesis, and increased ARE
binding activity and activation of Nrf2 signaling, which increase the binding
to promoters for oxidative stress-related and adipogenic genes, suggesting
the potential roles of PFOS regulating white adipose tissue expansion and
the related obesity.
The activation of Ppar-

by PFOS suggested that PFOS has Ppar-

independent mechanism, which is in agreement with the previous study
(Rosen et al., 2010).

PFOS increased liver weight and caused

hypertrophy, which related with the activation of peroxisome proliferator,
consistent with the effects of Ppar-

activator WY14,643.

Also, PFOS

induced both mouse and human Ppar-

activation, but exerted a greater

level of induction of mouse Ppar-

than human Ppar-
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at similar

concentrations (Takacs and Abbott, 2007). It has been reported that PFOS
increased Ppar- luciferance reporter plasmid activity at the concentration
from 1

M to 100

M, with little toxicity at 250

2007), illustrated that the dose 50

M (Takacs and Abbott,

M used in the current study is the

optimal concentration for PFOS treatment.
Ppar- activation is the key process for adipocyte differentiation in 3T3-L1
preadipocytes. Ppar- is needed for adipose tissue formation in mice, and
in a loss-of-function experiment, adipocyte differentiation and white adipose
tissue expansion was impaired, and did not develop glucose intolerance
and insulin resistance, suggesting the central role for adipogenesis (Jones
et al., 2005).

We failed to observe adipose tissue expansion in mice

administered with PFOS (0.1 mg/kg BW/day) for 6 weeks (Data not
shown). This lack of effect could be explained by the relatively low dose of
PFOS has been used in the current study, but is consistent with other
reports. Qazi et al. have used 0.005% (W/W) dietary treatment of PFOS
for 10 days with male mice, resulted in significant reductions for serum
cholesterol and triglycerides content (Qazi et al., 2010). And male BALB/c
mice fed with HFD with the exposure of PFOS at the dose of 5 or 20 mg/kg
BW/day for 14 days, exhibited reduced serum lipid and lipoprotein content,
but significantly increased hepatic lipid accumulation, probably via Pparαindependent pathway (Wang et al., 2014). Also, compared to liver, PFOS
deposits to a much lower concentration in white adipose tissue (Maestri et
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al., 2006). So perhaps the low dose of PFOS administered might not have
a positive induction in adipose tissue expansion in vivo, despite this
treatment inducing adipogenic gene expression at transcriptional levels.
The second possible reason is that PFOS has a potential function to induce
Ppar- activation (Shipley et al., 2004). Increased Ppar- in adipose tissue
could induce lipolysis and promote β-oxidation (Reddy and Hashimoto,
2001; Goto et al., 2011), which is beneficial to prevent the lipid
accumulation to adipose tissue and decrease white adipose tissue mass. It
was noted that contradict results have been reported that PFOS
administration reduced white adipose tissue mass, the ventral fat was
significantly reduced when mice treated with PFOS (20 mg/kg BW/day) for
14 days, even in normal diet and HFD-group, which related with the
reduced secretion and impaired function of low density lipoproteins (Wang
et al., 2014).
It is interesting to note that PFOS increased insulin-stimulated glucose
uptake in differentiated adipocytes. A previous study reported that higher
serum PFOS concentration was positively associated with increased serum
insulin levels and insulin resistance (Lin et al., 2009), which contrasts with
the current study. And Nelson et al. reported that higher serum PFOA and
PFOS concentration was positively associated with serum cholesterol
levels, but displayed a weak association with body weight and insulin
resistance (Nelson et al., 2010). Another in vivo study performed on rats,
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which the pregnant rats were given with PFOS (0.5 or 1.5 mg/kg BW/day)
from gestation day 0 to postnatal day 21. The pups displayed impaired
glucose tolerance and enhanced insulin resistance index, suggesting
PFOS disrupted insulin signaling in integrate animal study (Lv et al., 2013).
In the current in vitro study, we demonstrated that PFOS increased insulininduced glucose uptake and increased gene expression related to insulin
signaling. One possible reason is that PFOS increased adipogenesis in
3T3-L1 preadipocytes and enhanced adipogenesis increases capacity for
glucose uptake (Nugent et al., 2001). Also, enhanced Ppar- and Glut4
expression will help to promote glucose uptake, as well as improve insulin
signaling and insulin-response activity. Our previous study reported that
enhanced Nrf2 activity by Keap1-KD increased glucose tolerance, and
increased insulin-stimulated Akt phosphorylation without Glut4 expression
change (Xu et al., 2013), suggesting activation Nrf2 can promote insulin
signaling, contribute to positively regulate glucose uptake in differentiated
3T3-L1 preadipocytes.
The study herein reported that PFOS could induce Nrf2 activation in
preadipocytes. PFOS administration has been shown to increase ROS
production, which induces oxidative stress and activate Nrf2 signaling
(Qian et al., 2010). ARE consensus elements are the typical transcriptional
factor binding sites, which are described to induce the antioxidant gene
expression for Nrf2 target genes, such as Ho1, Gclc, Nqo1, and Multiple
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resistance-associated proteins to provide a protective role against oxidative
and cytochemical stress (Nguyen et al., 2009). Also, ARE sites have been
reported in the promoter of Pparγ and Cebpα, which are responsible for
3T3-L1 preadipocytes adipogenesis (Pi et al., 2010). ARE binding was
enhanced after PFOS treatment in MEFs isolated from transgenic mice that
harbor a ARE sequence coupled to a hPAP reporter, suggesting activation
of genes via ARE sites is a process that occurs via PFOS-induced
adipogenesis. Chip assay revealed that PFOS treatment increased Nrf2
binding to ARE sites in the mouse Nqo1 promoter in 3T3-L1 cells cultured
in induction media for 4 days, further confirming that PFOS administration
can induce Nrf2 signaling via ARE binding during adipogenesis.
Overall, this study reported that novel effects of PFOS in inducing
Ppar-

and Cebp-

expression and adipogenesis, via enhancing ARE

binding activity and Nrf2 signaling in preadipocytes (Figure 7D).
Additionally, PFOS increased insulin-stimulated glucose uptake and
increased gene expression related with insulin signaling. This study points
out the potential roles of PFOS promoting adipose tissue differentiation and
the related metabolic conditions of obesity consequentially.
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3.8 FIGURE LEGENDS:
Figure 1. MTT assay of PFOS on 3T3-L1 preadipocytes. The illustration
of study design on (A) 3T3-L1 preadipocytes, (B) human visceral
preadipocytes, and (C) mouse embryonic fibroblasts.

(D) 3T3-L1

preadipocytes were exposed to PFOS at concentration of 1nM, 5nM, 10nM,
100nM, 500nM, 1 M, 5 M, 10 M, 50 M, 100 M or DMSO in DMEM with
10% FBS for 48 hrs. PFOS toxicity at different dosage was determined by
MTT assay. N=5. *, P<0.05, PFOS-treated vs. vehicle (Veh).

Figure 2. Non-cytotoxic levels of PFOS enhances lipid content in
differentiated 3T3-L1 preadipocytes.

Cells were differentiated 2 days

post 100% confluences (Day 0) by switching with differentiated media
containing

10 g/mL

insulin,

1 M

dexamethasone,

0.5

mM

isobutylmethylxanthine in DMEM with 10% FBS for the ﬁrst 3 days; then
switch to media only containing 10 μg/mL insulin in DMEM with 10% FBS
for the additional 5 days. Indicated concentration of PFOS or vehicle was
included in media from Day 0 to Day 8. (A) Representative images of Oil
red O staining of 3T3-L1 preadipocytes at indicated concentration of PFOS.
(B) Lipids were extracted from differentiated 3T3-L1 adipocytes by using
chloroform/ methanol mixture, and triglycerides (TG) content was
determined spectrophotometrically. Relative triglycerides content (%) was
displayed using differentiated media containing DMSO (0.1%) - treated
cells as a standard (Veh). *, P<0.05, PFOS-treated vs. vehicle (Veh).
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Figure 3. PFOS increases adipogenic gene expression and induced
Nrf2 signaling in 3T3-L1 preadipocytes.

3T3-L1 preadipocytes were

induced to differentiation to adipocytes with or without PFOS (50 M) for 3
days.

Total RNA was extracted at the indicated time.

levels were quantified by quantitative real-time PCR.

Relative mRNA
PFOS increased

adipogenic gene expression of Cebp- , Ppar- , Fabp4, Lpl (A), and
increased Nrf2 signaling of Nrf2, Nqo1, Gclc (B) mRNA levels in 3T3-L1
preadipocytes All data were normalized to 18S rRNA levels. *, P<0.05,
PFOS-treated vs. vehicle (Veh)..

Figure 4. PFOS promotes insulin-stimulated glucose uptake in 3T3-L1
adipocytes. (A) 3T3-L1 preadipocytes were induced to differentiation to
adipocytes for 10 days, then treated with PFOS (1, 5, 10, 50, 100 M) for 5
hrs.

Glucose uptake of differentiated 3T3-L1 preadipocytes was

determined by using 2-NBDG according to the manufactory instruction.
The fluorescence activity was monitored at an excitation wavelength of 485
nm and an emission wavelength of 535 nm. Relative glucose uptake was
displayed using vehicle-treated group as a standard.

Total RNA was

extracted from 3T3-L1 adipocytes after treated with PFOS (10

M or 50

M) for 5 hrs. Relative mRNA levels of (B) Ppar- , Srebp-1c, Glut4, Irs-1,
Insr and (C) Nrf2, Nqo1 were quantified by quantitative real-time PCR. All
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data were normalized to 18S rRNA levels. *, P<0.05, PFOS-treated vs.
vehicle (Veh).

Figure 5. Adipogenic gene expression and Nrf2 signaling of Nrf2 and
Nqo1 expression increase in white adipose tissue (WAT) from mice
administered PFOS.

Mice were administrated with PFOS (0.1mg/kg

BW/day) for 6 weeks. Epididymal white adipose tissue was collected and
total RNA was extracted. (A, B) Relative mRNA levels of the indicated
gene were quantified by quantitative real-time PCR.

All data were

normalized to 18S rRNA levels. *, P<0.05, PFOS-treated vs. vehicle (Veh).

Figure 6. PFOS increased lipid accumulation in differentiated human
visceral preadipocytes.

Human visceral preadipocytes obtained from

Lonza were induced to differentiation to adipocytes by switch with the
differentiated media contain dexamethasone, isobutylmethylxanthine and
insulinSingleQuotsTM according to the manufacturer’s instructions, with
PFOS (5 or 50 M) or not (0.1% DMSO) for 11 days. (A) Representative
images of Oil Red O staining of differentiated human visceral preadipocytes
treated with PFOS at indicated concentration. (B) Staining of lipids was
extracted from differentiated human visceral preadipocytes via isopropanol
isolation, and the lipid content was determined spectrophotometrically.
Relative lipid content (%) was displayed using differentiated media
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containing DMSO (0.1%) - treated cells as a standard (Veh). *, P<0.05,
PFOS-treated vs. vehicle (Veh).

Figure 7. PFOS increases hPAP expression and enhances Nrf2
enrichment at ARE sites in mouse Nqo1 promoter.

(A) Mouse

embryonic fibroblasts isolated from ARE-hPAP transgenic mice were
induced to differentiation to adipocytes for 4 days, then incubated with
PFOS (50 M) for additional 4 days. Total RNA was extracted and hPAP
mRNA levels were quantified by quantitative real-time PCR. All data were
normalized to 18S rRNA levels. *, P<0.05, PFOS-treated vs. vehicle (Veh).
(B) 3T3-L1 cells were induced to differentiation for 2 days. Cells were
collected for chromatin immunoprecipitation assays using either Nrf2
antibody or IgG as the negative control. A primer targeted for antioxidant
response element in mouse Nqo1 promoter was used for PCR
amplification. Non-immunoprecipitated chromation (1%) was used as an
input control.

(C) Relative ChIP signal for PFOS function on Nrf2

enrichment to ARE element of mouse Nqo1 promoter. (D) The work-flow
for PFOS increased adipogenesis via activating Nrf2 signaling and inducing
Cebp- , Ppar- expression in preadipocytes.

107

3.9 FIGURES:
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3.10 SUPPLEMENTARY MATERIALS:
Supplementary table 1. Primer sequences for quantitative RT-PCR
Genes
Cebp-α

Forward

Reverse

CAAGAACAGCAACGAGTACCG

GTCACTGGTCAACTCCAGCAC

TTCTGGTGCTTGTCTCACTGA

CAGTATGTTCGGCTTCCCATTC

Fabp4

AAGGTGAAGAGCATCATAACCCT

TCACGCCTTTCATAACACATTCC

Glut4

GTGACTGGAACACTGGTCCTA

CCAGCCACGTTGCATTGTAG

Gclc

GGGGTGACGAGGTGGAGTA

GTTGGGGTTTGTCCTCTCCC

hPAP

TTGCCCCAAATCTCAACTTC

TGGGTAGCTGGGACTACAGG

Insr

ATGGGCTTCGGGAGAGGAT

GGATGTCCATACCAGGGCAC

Irs-1

TCTACACCCGAGACGAACACT

TGGGCCTTTGCCCGATTATG

Nqo1

AGGATGGGAGGTACTCGAATC

TGCTAGAGATGACTCGGAAGG

LPL

GGGAGTTTGGCTCCAGAGTTT

TGTGTCTTCAGGGGTCCTTAG

Nrf2

TCTTGGAGTAAGTCGAGAAGTGT

GTTGAAACTGAGCGAAAAAGGC

Ppar-

CTCTGTTTTATGCTGTTATGGGTGA

GGTCAACAGGAGAATCTCCCAG

Srebp-1c

GCAGCCACCATCTAGCCTG

CAGCAGTGAGTCTGCCTTGAT

18S

AGTCCCTGCCCTTTGTACACA

CGATCCGAGGGCCTCACTA

2m
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SUMMARY AND CONCLUSION
1. Perinatal peripubertal exposure of bisphenol A increases predisposition to
NAFLD, in younger as well as adult mice. Developmental exposure of
environmental chemical like bisphenol A exerts epigenetic modification of
lipogenic genes. This gives a novel plausible mechanism of involvement of
early age epigenetic imprinting for rising prevalence of childhood obesity.
Childhood lipid homeostasis disturbances may have its roots in perinatal
toxicity of environmental chemicals.
2. PFOS exposure augmented differentiation of preadipocytes to adipocytes,
hence increased overall fat cell number. Thus, indirectly study has
demonstrated obesogenic property of PFOS.

PFOS also increased

glucose uptake in adipocytes.
3. In both BPA induced hepatic steatosis and PFSO induced adipogensis,
activation of Nrf2 was evident, supporting recent literature stating role of
Nrf2 in lipid homeostasis.

Using BPA/ PFOS as a model compounds,

novel mechanism of environmental lipid disturbances through Nrf2
mediation were elucidated.
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APPENDIX 1:
Objective: Studying the hepatic lipid accumulation with short-term high fat diet
feeding in Keap1 knockdown (Keap1 KD) mice
Experimental design: Nine week old WT and Keap1 KD mice were fed 10%
or 60% kCal fat diet for 5 weeks, and then euthanized to collect organs.
Tissue and serum lipid levels (TG, FFA, LDL/HDL) were detected by
commercial kits. For all the figures, differences between the groups were
calculated by two-way ANOVA followed by Tukey’s multiple comparison tests.
Asterisk * represents significant difference between WT and Keap1 KD mice,
whereas # represents significant difference between SD and HFD groups.
Synopsis: As elaborated in all the manuscripts in this thesis, elucidating role
of Nrf2 in lipid accumulation is one of the primary goals of my research. In this
project,

mice

having

diminished

expression

of

Keap1

protein,

and

subsequently constitutive activation of Nrf2 were utilized. After 5 weeks on
HFD, these mice appeared to be protected from lipid accumulation in liver.
Keap1 KD mice fed SD as well as HFD contained less hepatic lipids as
compared to WT controls (App 1 fig 2). TG content of the white adipose
tissue, on the contrary, was higher in Keap1 KD mice relative to controls, on
both diets. On both diets, Keap1 KD mice demonstrated increasing trend in
LDL/HDL ratio (App 1 fig 2). Lipogenic target mRNA and protein expression
was decreased in Keap1 KD mice on SD, and the expression was further
diminished in HFD fed groups (App 1 fig 4 and 5). Fatty acid oxidation target
expression data was inconclusive. Keap1 KD mice demonstrated high pAmpk
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α to Ampk α ratio, and this change was higher with HFD (App 1 fig 6). Ratio of
pIrs1 to total Irs1 decreased Keap1 KD in SD fed group, but not in HFD fed
group, compared to respective controls (App 1 fig 6).

118

119

120

121

122

123

APPENDIX 2:
Objective: Studying the effect of perinatal peripubertal (PNPP) effect of
bisphenol A (BPA) on hepatic lipid accumulation and its mechanism in female
mice
Experimental design: Pregnant mice were implanted with osmotic pumps
containing 250μg/kg BPA or vehicle. The pups were exposed to BPA after
birth through milk, and until week 5 of age through drinking water. One set of
animals was euthanized at week 5, whereas another set was euthanized at
week 39, without any further BPA exposure beyond week 5. The liver tissue
was used for lipid accumulation (TG, FFA content), mRNA expression (RTPCR), protein expression (western blot), promoter methylation (methylated
DNA

immunoprecipitation),

and

binding

assay

(chromatin

immunoprecipitation). This data is originally a cohort from studies described in
‘manuscript 2’, hence all the methods have been described in detail.
Differences between the groups were checked with Student’s t-test, asterisk *
represents significant difference between BPA treated and vehicle group.
Synopsis: The treatment group represented here, BPA 250μg/kg is another
treatment cohort from the same study that is presented in ‘manuscript 2’ of this
thesis. Simultaneous study with BPA 25μg/kg and 250μg/kg were performed,
and data was compared with vehicle group. Hepatic lipid accumulation (liver
TG and oil red o staining) was significantly increased with BPA 25μg/kg but not
with BPA 250μg/kg. This is the reason study with this exposure level of BPA
was not included in original manuscript.
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Although phenotypic increase in

hepatic lipids was not evident in BPA 250μg/kg (App 2 fig 1), lipogenic gene
expression (App 2 fig 2), protein expression (App 2 fig 3 and 4), Nrf2 signaling
(App 2 fig 5), and lipogenic promoter hypomethylation (App 2 fig 6) was
altered similar to BPA 25μg/kg exposure.

Nrf2 binding on the Srebp-1c

promoter was not enhanced by BPA 250μg/kg exposure (App 2 fig 7),
indicating transcriptional mechanism of Nrf2 mediated lipid accumulation in
liver is evident only in BPA 25μg/kg exposure, but not in BPA 250μg/kg.
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